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ABSTRACT
DO NO HARM: PRESCRIPTION DRUG ABUSE AND THE
PARAPROFESSIONALISM OF PHARMACISTS
by
Kathrine Barnes
The University of Wisconsin-Milwaukee, 2013
Under the Supervision of Professor Paul Brodwin

History reveals long, intertwining chronologies between licit and illicit drugs, and social
change. Currently, rates of prescription drug abuse are increasing and medical
professionals at every step must mediate the flow of pharmaceuticals. The effect of the
epidemic on emerging social change relative to pharmacy remains unexplored. While
pharmacists are trusted and have shown to be effective in smoking cessation, little
research has explored the impact of prescription drug abuse on their work. Pharmacists
have little official authority and autonomy on the job, relegating them to the level of
paraprofessionals, but pharmacists find novel ways of gaining agency in their day-to-day
work. In conceptualizing addiction as a patient who lacks awareness and whose mind is
fragmented by the action of drugs on their body, pharmacists are able to hassle patients
and attempt to bring awareness of their condition through an assemblage of patient
records comingled notions of profit, care, biomedicine, a global pharmaceutical market,
and morality. While relying heavily on physicians to do their work, pharmacists blame
prescribers for the actions of their patients. In seeing patient’s patterns of use, not the
effects of the drug, at issue in creating addiction to prescription drugs, pharmacists
insulate their position of low authority, effectively relegating the problem to doctor’s turf,

	
  

ii	
  

	
  
and absorbing a dialogue of the global pharmaceutical industry while actively
constructing the effect of prescription narcotics on the addicted body. Through
pharmacists’ work, those impacted by the prescription drug abuse problem can ascertain
what happens when the drugs meant to heal the public become profound agents of harm.
Pharmacists and the rest of the medical community are subordinated by a language and
conceptualizations rooted in the pharmaceutical industry.
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Chapter I: Introduction
The fallout began in 2006. That year, researchers at the Center for Disease
Control authored a monumental study showing a significant increase in deaths among
women who abuse prescription narcotics with a concurrent 500 percent increase in the
prescribing of such drugs (Paulozzi, Budnitz, Xi 2006). Immediately, representatives of
the University of Wisconsin Pain & Policy Studies Group, Aaron Gilson and David
Joranson (2006), refuted these conclusions, cautioning against tightening regulation of
the drugs: people are in pain; we have a duty to absolve them of pain. Their names litter
other literature on the dangers of underprescribing—as a citation in a book published by
the Human Rights Watch entitled Please Do Not Make Us Suffer Anymore: Access to
Pain Treatment as a Human Right (2009:5), in the Journal of Pain and Symptom
Management (2002), and in the Indian Journal of Palliative Care (2005). As a 2011
investigative report by the Milwaukee Journal-Sentinel found, hidden by this record is a
generous and ongoing financial relationship with several pharmaceutical companies, the
largest donation of which coming from Purdue Pharma (Fauber 2011a). Between 1999
and 2010, Purdue Pharma paid the UW Pain & Policy Studies Group over $1.6 million
according to the Milwaukee Journal-Sentinel. The group’s total pocketed profit from
pharmaceutical companies exceeds $2.5 million. Purdue Pharma is the producer of
OxyContin, an expensive, highly addictive narcotic. Users put a pill of Oxycodone onto a
piece of foil, light it from underneath, and using a straw, inhale the fumes. The following
year, in 2007, Purdue was brought up on charges by the United States Department of
Justice for fraudulently misleading prescribers in saying OxyContin was less addictive
than other pain medications (Meier 2007). The company and three of its executives plead
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guilty to various charges and over $635 million in fines were imposed on Purdue Pharma.
Despite this, OxyContin continued to be prescribed at high rates, largely fueled by claims
furthered by the palliative care movement and the UW Pain & Policy Studies Group.
Gilson and Joranson had an unexpected path to the organization. While making
prescribing recommendations to doctors in peer-reviewed journals, neither has an M.D.—
according to the UW Pain & Policy Studies Group website, Gilson has a doctorate of
social welfare and Joranson, his masters in social work.
A year after the UW Pain & Policy Studies Group story broke Daniel Lee had a
problem. He probably was not aware of the controversy being played out about 90 miles
away from Milwaukee where he lived and operated as a small time drug dealer.
Nonetheless, he had customers clamoring for OxyContin. Text messages to his phone
indicated several of his customers asking for Oxycodone 30s (USDOJ 2013). The
problem was that Daniel had none. So, Daniel made a decision. He searched on his phone
for local pharmacies, removed the license plate from his car, and on January 2nd, 2012
around 1pm, he donned a gray hooded sweatshirt along with a thick black winter coat, a
knit cap, a scarf, two sets of handcuffs, and a gun and walked into Thompson Serv-U
Drugs. He walked out shortly thereafter with cash and narcotics (Docter 2012). While
news outlets reported on the incident, Lee was not immediately apprehended. So, he
robbed three more pharmacies in a similar fashion over the next two months. In May of
2012, Lee had a new problem: he was arrested and charged with seven federal felonies.
He was sentenced to 65 years in prison (USDOJ 2013).
While the professional and privileged role of Gilson and Jorenson existed a world
away from the life of small-time drug dealer Daniel Lee, their experiences are united by
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the sale and distribution of prescription narcotics. It can be easy to cast these incidents off
as the acts of three morally misguided individuals; however, their stories merely skim the
surface of a multi-billion dollar industry in pharmaceuticals. These incidents demand a
deeper analysis; an analysis to properly contextualize the distribution of prescription
narcotics.
Research is quick to pin the blame on prescribers and the industry as a whole.
While I do not dispute the legitimacy of these claims, pharmacists are embroiled in this
conflict in ways both unexpected but illustrative of the wider problem. The proliferation
of pharmaceutical products throughout society in a variety of licit and illicit contexts is
indicative as much of liberal prescribing as consumer demand: both spheres are driven by
deeper conceptualizations of the power of prescriptions to effect change, be it curative,
therapeutic, or addictive. While doctors are the primary power-holders in the medical
hierarchy, pharmacists immerse themselves through years of training and on the job
practice in pharmaceuticals. They represent the link between the liberal prescribers
targeted by Gilson and Jorenson, and the use of medications in the community, whether
they are legitimately and “responsibly” taken or bought from the Daniel Lees of the
streets. Yet, for all the research on prescription drug abuse, the pharmaceutical industry,
and doctor-patient interactions, research takes for granted pharmacists’ work.
Pharmacists’ knowledge deals intimately with the therapeutic effects, side effects,
and contraindications of pharmaceuticals. By definition, their job is to exchange a
doctor’s script for the medication itself. Pharmacists are what is termed paraprofessionals,
professionals without the full trappings of doctors and must rely on prescribers for their
work (Freidson 1988). The field has undergone an expansion in recent times as pharmacy
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has taken on additional duties, such as administering vaccinations, blood pressure
consultation, and advising on prescribing in certain hospital settings. Additionally,
research has shown pharmacists to be highly trusted by the public (Gallup 2013) and
effective in smoking cessation (Maguire, McElnay, & Drummond 2001). Considering
their unique positionality with regards to medications, as well as the demonstrated role
pharmacists can have in patient health, pharmacists’ encounters with prescription drug
addiction including how they conceptualize drugs and patients are worth documenting.
Furthermore, prescription drug abuse warrants a deeper analysis of the literature.
Epidemiological studies have shown this problem to be unique from the abuse of
classically illicit drugs. Prescription drug abuse is increasing at both ends of the age
spectrum, particularly among Caucasians, and is spreading to rural areas (Manubay,
Muchow, & Sullivan 2011). The abuse of street drugs, in contrast, has generally been
described as a problem of urban areas and more prevalent among minorities than has
been observed with prescription drug abuse (Swendsen et al 2012). Additionally,
prescription drugs of abuse construct a liminal space between the legal, non-abusable
pharmaceuticals on the market, such as antibiotics, with a clear therapeutic value, and
entirely illicit street drugs, such as marijuana, heroin, or cocaine. The fact that
prescription narcotics need to first be acquired with the permission of a doctor and
dispensed by a licensed pharmacist calls into question the professional roles of these
actors—how are abusers able to acquire controlled prescriptions for illicit purposes?
Additionally, prescription drug abuse provides a useful analytic ground in which to
examine the role of drugs—therapeutic or otherwise—in creating and recreating both the
self, as a body and addict, and the professional role of pharmacists.
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In fact, the juncture of pharmacy and drug abuse is in-and-of-itself not a novel
analysis—pharmacy and street drugs have shared a relatively long history. Drugs that
today are readily categorized as illegal, such as cocaine, were once used to treat illness
(Acker 2002:2-9). It was only when these substances began to spread into immigrant and
minority populations that the morality of consuming these substances began to be
questioned. Quickly, the tide of public opinion began to ebb in the direction of increasing
legal penalties for the use and illicit sale of such drugs. Demand for substances now
synonymous with the lower classes waned among upper-class, predominately white
naturalized citizens and beginning in the early 1900’s, drugs such as marijuana, heroin,
and cocaine were slowly outlawed. By the time drugs were codified into the Controlled
Substances Act of 1970 by President Nixon, regulating the prescribing or prohibition of
all drugs, the pharmaceutical market had become firmly enmeshed into American society.
Thirty years earlier, in the 1940s, Pfizer developed a large-scale fermentation technique
able to produce record quantities of penicillin (Williams 1984:124). A decade later in
1957, the invention of the discreet, female-controlled administration of the birth control
pill for contraception set the stage for the women’s liberation movement of the 1960s
(Gordon 2002). While previous forms of birth control were male-controlled, “the pill” put
birth control firmly and nearly completely in the hands of women and harkening a
reorientation towards women’s decision-making. The ability of pharmaceuticals to not
only direct sociocultural change, but generate record profits was clear, most of all to
pharmaceutical companies now in a feeding frenzy for the drug of the future. The next
revolution of drug development is generally described as the invention of drugs for
psychiatric care, namely fluoxetine, or Prozac, by Eli Lilly and Company in 1977 for the
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treatment of depression, but it was not formally launched until 1988 (Healy 2006). The
range of drugs marketed to treat psychiatric conditions became a fruitful market for the
pharmaceutical industry of rather epic proportions, their profits bolstered by increased
allowance for direct to consumer marketing for pharmaceuticals in 1969 (Ventola 2011).
As the deinstitutionalization movement of the psychiatric population in the 1960’s and
1970’s occurred, moving large numbers of the indigent population out of hospitals and
mental health wards and into the community, these drugs offered a therapy administrable
in an out-patient setting (Szasz 2007).
By 1978, Knoll Pharmaceuticals (now Abbott Laboratories) had introduced
Vicodin, composed of five milligrams hydrocodone and 500 milligrams of
acetaminophen, or ibuprofen (New York Magazine, 2009). While hydrocodone along
with opium and morphine is a strictly-regulated Schedule II drug, when mixed with
acetaminophen, it can be more loosely regulated as a Schedule III drug (United States
Food and Drug Administration, 1970). While the Controlled Substances Act (1970) does
not permit Schedule II drugs to be refilled, Schedule III drugs can be refilled up to five
times in a six-month period. Then, patients have access to four times the drug without the
inconvenience of having to return to their doctor. Thus, for pharmaceutical companies,
the looser restrictions on Schedule III drugs equate to more profit. While Vicodin’s patent
expired in 1983, making the generic version available at a cheaper cost to consumers, a
variety of other prescription narcotics were patented and sold (New York Magazine,
2009). In 1995, the FDA approved OxyContin produced by Purdue Pharma as a Schedule
II drug (FDA, 1995). The product remains under patent as of this writing and not only a
huge contributor of Purdue’s profits, but a primary drug of abuse. In 2002, sale of these
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drugs had increased 500 percent since 1990 and by 2006, 130 million prescriptions were
being written for hydrocodone products (Paulozzi, Budnitz, Xi 2006). In a New York
Magazine (2009) spotlight on the history of Vicodin, the Director of Pain Medicine at
NYU, Dr. Chris Gharibo describes the “product loyalty—to physician practice patterns
that are very Vicodin-based” (2009). Despite concerns regarding the effect of these drugs
on the liver, Vicodin, hydrocodone, and OxyContin continue to be prescribed for and
dispensed at record rates, driving rates of the illicit use of these drugs ever higher.
As this brief history illustrates, illicit as well as licit drugs, sociocultural change,
pharmacy and the pharmaceutical industry have a long and intertwined story. Drug
regulation both creates and re-creates social structures—stigmatization of immigrants,
minorities, and the indigent—and the pervasiveness of these drugs throughout society
fuel a diverse array of changes from women’s liberation to deinstitutionalization. Even
today, cocaine, a drug largely associated with upper class white men, although
chemically similar to crack, a smoke-able form more favored by African American
populations, carries a lighter legal sentence (Sklansky 1994). African Americans, who
make up the majority of drug convictions, are more likely both to be arrested and spend
longer in jail for drug charges than Caucasian criminals. Such racial divides exist in the
prescribing of prescription narcotics, with doctors prescribing narcotics at significantly
higher rates to Caucasians than minorities (Pletcher 2008). Despite this, as I witnessed in
the conduction of my fieldwork, prescription drug abuse is often colloquially viewed as a
minority drug problem, despite epidemiological trends to the contrary. Drugs, regardless
of their legal classification, not only constitute an important driving force to sociocultural
change to which pharmacists are often actors in, but the production, dispensing, and
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consumption of these drugs constitutes an historically-rooted moral act. Thus, a critical
analysis of pharmacists, whose work most intimately involves the exchange of scripts and
money for drugs, offers a useful, but underutilized, ground for exploring questions of
drugs, the pharmaceutical industry, the self, and the impact of these elements on
professional roles.
To explore these questions and in the midst of the Daniel Lee and UW Pain &
Policy Studies Group dramas, in February 2012, I began a four-month field project on the
training and practice of pharmacy in the context of prescription drug abuse. I attended
several lectures at a school of pharmacy in the upper Midwest and interviewed several
practicing pharmacists—some newly placed out of school in corporate settings, others
well established in community pharmacies. Their struggles in combating prescription
drug abuse both practically and ethically, as well as the training they receive on the
proper dispensing of medications from antibiotics to OxyContin, reveal a group of
individuals grappling with a problem that has no easy solution in sight. Their words and
actions are a testament to the difficulty of attempting to deal with a long-standing,
ingrained problem from a position of low authority and low autonomy. Pharmacists
described the multitude of ways they psychologically and practically, always creatively,
cope with having little on-the-job decision-making.
My central thesis is: the conflicts that emerge regarding the (il)licit use of
prescription drugs allows the professional role of pharmacists and the addicted body to
become sites where micropolitics between dialogues of medicine and care compete with a
pharmaceutical industry agenda centered on profit-generating work. Straddled between
profit and care, pharmacy presents a workable metaphor for the development of medicine
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and its increasing reliance on the products of the pharmaceutical industry. In how
pharmacists describe addicts, I will show how their words resonate with the way they
describe their own work. They describe individuals they suspect as abusing drugs as
either a “true patient” in need of the medication-as-therapy, or an addict, as individuals
unaware of their dependence. Nevertheless, as paraprofessionals, pharmacists are often
forced to dispense to those they believe are addicts with no medical need for prescriptions.
The resultant futility and ambivalence they feel towards their work and the products of
this labor is ameliorated in part by blaming physicians who they feel misprescribe
narcotics in the wrong amounts to the wrong people. Beholden to the idea that drugs are
good and only one’s use of a medication can be bad, pharmacists rely on an “assemblage”
of technologies, different iterations of patient records, to legitimize their work, attempt to
bring awareness of addict’s problems to addicts, and portray their labor as more moral—
i.e., the pharmacists’ drugs are good, but the doctor’s patient is bad. The definition of
care they produce centered on this dictum reflects a larger theoretical tension surrounding
pharmaceuticals: what are the pharmaceuticals that both treat disease and cause disease?
The medicalization of addiction, casting it as a disease state, and “pharmaceuticalization”,
which perpetuates drugs through society, demand a new definition of therapeutic care and
of the work dedicated to delivering this care.
My analysis will begin with a review of the existing literature. As the brief history
presented earlier introduced the historical derivation for my inquiry, these historical
precedents will be built upon and contextualized through modern epidemiological studies,
literature on the sociology of professions, analysis of the pharmaceutical industry—the
manufacturing of its products as medicinal and social items—as well as framing my
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argument through the lens of Latour’s Actor Network Theory (2005). Next, I hope to
address how my methods are uniquely situated to answer the questions that I pose. My
primary data chapters will present support for the arguments introduced above. First, I
will describe the unique tensions pharmacists feel as paraprofessionals equally situated
between the worlds of care and profit. I will describe their two ethos centered on these
worlds and how they collide when dispensing drug of abuse for profit to addicts whom
they believe are harmed, not helped, by prescription narcotics. By conceptualizing addicts
as unique from patients, pharmacists construct a new ground upon which to antagonize
addicts and attempt to keep the medications from going into their hands. Yet, as rising
prescription drug abuse rates attest to, their efforts often fail their objectives. For this,
pharmacists place a great deal of blame on prescribers. Such blame serves both to set the
boundaries of their profession, centered upon the medications, as distinct from
prescriber’s realm concerned with patient diagnoses and treatment outcomes. Yet, their
reliance on doctors to write scripts that predicate pharmacist’s labor creates an overall
feeling of ambivalence on the part of pharmacists towards prescribers. Their small acts of
defiance, blame, and patient hassling allows pharmacists the liberty granted them by their
paraprofessional role; by readily working from such a constrained position, they avoid
shouldering the blame for the problem their labor creates. Thus, their ambivalence
legitimates their position as dependent upon, but unique from, prescribers. To further
combat the futility of dispensing to those they suspect have no “legitimate” demand for
the medication, pharmacists produce a collection of patient records, the only tangible
product of their suspicions. These records are available to other locations within a
corporate chain, or possibly to doctors, police officers, and others through Prescription
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Drug Monitoring Programs (PDMPs). These records compose an assemblage, meant to
bring awareness of the drugs’ effects to addicts. A specific definition of care emerges.
While decidedly centered on pharmaceuticals, pharmacists continually grapple with the
juxtaposition of their training, which proffers pharmaceuticals as panaceas to any array of
ills, with the reality that some of these pharmaceuticals produce an ill themselves, that is
prescription drug abuse.
Ultimately, this tension is not unique to pharmacy, but representative of all
domains of medicine. In a medicalized society that creates diagnoses for an increasing
number of human states in an era of pharmaceuticalization that produces a never-ending
stream of medicines to treat these ills, the bodies constructed through these processes of
care, as well as the nature of care itself is radically transformed. Any answer to the
prescription drug abuse epidemic will have to address these fundamental questions.
Meanwhile, the hegemony of the pharmaceutical industry renders the medical community
conceptually ill equipped, operating from a similarly constrained and futile position, to
attempt to hedge the burgeoning abuse epidemic.
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Chapter II: Literature Review
The supremacy with which physicians are afforded within the context of the
medical field is intuitively known, so as to be nearly an a priori assumption. Researchers
have adopted this stance as well, elucidating several nuances to doctor-patient and
doctor-pharmacist interactions into a long history on the subject of doctors’ role in
delivering healthcare. The fact that physicians have a higher degree of professional
autonomy in their jobs relative to other healthcare professionals, such as pharmacists,
warrants this line of inquiry. Within the prescription drug abuse literature in anthropology,
which is scant, doctor’s authority and autonomy on the job provide the most obvious
research interest, as they are the first gatekeeper (for lack of a better word) abusers
encounter in gaining possession of prescriptions to abuse. Most research on prescription
drug abuse seems predicated on the notion that altering doctors’ decision making offers
the best site of intervention to eradicate or at least slow down or understand the
increasing rates of prescription drug abuse.
However, as I will argue herein, pharmacists who experience work characterized
by multiple professional constraints offer another profitable site of inquiry. Not only are
pharmacists the only healthcare professionals who handle the medications people abuse,
but pharmacists also exist on the interstice between profit generating business and the
realm of healthcare concerned with patient care. I proffer the reorientation of drug abuse
and addiction literature to accommodate what I identify as the unique set of
circumstances surrounding the acquisition of prescriptions for illicit use (in contrast to
classically illicit drugs of abuse), the role of cultural notions of drugs, the body, and
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cognitive experience, as well as the professional role of pharmacists can lend to an
understanding of drugs, society, and professionalization in general.
Epidemiology. Prescription drug abuse is defined as the use of drugs targeting the
central nervous system taken for nonmedical purposes. While rates of prescription drug
innovation measured by spending and the emergence of new medications has declined
since 2007 (Aitken, Berndt, & Cutler, 2009), rates of prescription drug abuse escalated
during this time (NIDA, 2011) meaning increasing rates of prescription drug abuse are
not driven by an increase in the number of abusable drugs available. 7 million
adolescents reported abusing pharmaceuticals and 5.1 million of these cases involved
painkillers. In fact, the use of prescription drugs such as Vicodin and Adderall are
eclipsed only by marijuana. According to NIDA (2011), the rate of increase for
prescription pill abuse (94 percent) between 1992-2003 exceeded the rate of increase for
any other drug. Meanwhile, between 1991-2010, prescriptions for stimulants increased 9fold (5 million to 45 million) and prescriptions for opioid analgesics increased 6-fold (30
million to180 million). Specifically, pain relievers such as Vicodin and OxyContin
constitute the pills of choice for most abusers. The use of oxycodone HCl with at least
one other opioid was reported by 92 percent of users. Abuse is increasing at both ends of
the age spectrum—young adults and those aged 65 or older report increasing use of nonmedical prescription use between 2002-2007 (Pletcher 2008). Such users are 8 times
more likely to concurrently abuse tranquilizers and 5 times more likely to concurrently
abuse prescription opiates (Aitken, Berndt, & Culter, 2009). In contrast, rates of polydrug
abuse in abusers of classically illicit drugs are comparatively lower, particularly when
marijuana and alcohol are not considered, as these drugs have universally high rates of
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abuse across most demographics. Additionally, classically illicit drug abuse is
overwhelmingly limited to adolescents and young adults (Compton et al, 2005). Thus, the
epidemiology of prescription drug abuse differs significantly from the abuse of
classically illicit drugs.
Furthermore, prescription drug abuse is unique from other forms of drug abuse in
that Caucasians use at a higher rate than Hispanics or African Americans across all
classifications of prescription drugs—stimulants, anxiolytics, and opioid analgesics (Ford
& Rivera, 2008; Gunter et al., 2012; Kroutil et al., 2006; McCabe, 2005; McCabe et al.,
2006; Simoni-Wastila & Strickler, 2004; Sung et al.; 2005). Additionally, conflicting
reports exist as to whether education is a protective factor in prescription drug abuse as
with use of other drugs (Gunter et al., 2012; Harrell & Broman, 2009; Huang et al., 2006;
Merline et al., 2004).
Nonmedical use of prescription drugs also differs from abuse of classically illicit
drugs in that individuals are often introduced to prescription drugs through legal channels
as a result of organic maladies. When an individual develops tolerance and withdrawal,
the hallmarks of addiction, as the result of the legal use of a medication to treat a
medically diagnosed illness, what is termed “iatrogenic addiction” (Musto 1984). While
it is not currently known how many individuals currently abusing prescription
medications began in iatrogenic addiction, the number is potentially as high as the abuse
rate of opioids, the most abused class of prescription drugs. Opioids also constitute one of
the most prescribed classes of drugs on the market. Studies cataloguing the prescribing
rates of opioids have found physicians are more likely to prescribe opioid analgesics to
Caucasians. Additionally, the rate opioid analgesics are prescribed has increased with
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rates of abuse of these drugs (Pletcher et al., 2008). While this association does not
necessarily indicate causality, the correlating trends that suggest iatrogenic addiction are
intriguing. These data add another dimension to prescription drug abuse not seen in other
forms of abuse—that is, the potential that addicts previously, currently, or at some point
in the future may have a medical need for medications with an abuse potential. The fact
that drugs such as Adderall, Vicodin, or Valium shift between legality and illegality
complicate the study of prescription drug abuse.
Different demographics in prescription drug abuse compared to classically illicit
drugs and the different pharmacology of prescription drugs leads to new problems in
combating the problem. Approximately 60 percent of those taking prescription drugs for
non-medical purposes obtained the medications from a friend or family member (Aitken,
Berndt, & Cutler, 2009). According to NIDA (2010), those friends or relatives largely
report receiving the prescriptions for these medicines from only one doctor (81.7 percent).
Acquisition from street dealers (4.3 percent) or the internet (0.4 percent) constitutes a
small fraction of the pills abusers take. The issues arising from this fact are twofold. On
one hand, current literature predominately discusses preventing prescription drug abuse
through education to providers about the “warning signs” of addicts. However, this
statistic indicates that prescribers are often not coming into contact with the abusers
themselves. A knowledge gap exists in how information into how prescription drug
abusers acquire drugs and conceptualize their use could inform prevention aimed at
prescribers or pharmacists. Secondly, this statistic indicates that the acquisition of
prescription drugs occurs through channels unmediated by formal control. Whether
friends or family members knowingly provide drugs to abusers or if abusers steal the
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medications without the knowledge and consent of those the medications are prescribed
to is not known. Additionally, unlike illicit drugs acquired through drug dealers who are
likely more or less strangers, exchanges of prescription drugs are occurring through
established personal relationships. The different ways prescription drugs are acquired and
motivations for the use of these drugs relative to classically illicit drugs in light of
increasing rates in both older and younger Americans demands new ways of
conceptualizing prescription drug abuse.
Thus, prescription drug abuse differs epidemiologically from the abuse of street
drugs namely in the emergence of abuse of such drugs amongst Caucasians, across the
age spectrum, and through legal and legitimate prescribing of drugs of abuse otherwise
known as iatrogenic addiction. Opioid abuse constitutes the classification of drugs largely
considered of most concern due to users switching to heroin when access to prescription
opiates wanes (Wisconsin Department of Justice 2013). Heroin abuse, although similar in
chemistry and effects to prescribed opiates, introduces concomitant risk of HIV/AIDS or
hepatitis C transmission through the use of hypodermic needles along with increased risk
of death from overdose as street heroin can vary greatly in potency.
Prescription Drug Monitoring Programs (PDMPs). These data have contributed
to a swell of public attention both inside and outside the academic sphere towards
prescription drug abuse. Research is only beginning to expand beyond description
epidemiological work, including evaluations of prescription drug monitoring programs
(PDMPs). Sometimes simply referred to as Prescription Monitoring Programs (PMPs),
such programs track medications dispensed to patients across the state. Federal justice
programs and the U.S. Department of Justice offer grants for states to implement PDMPs
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in their states. Currently, 37 states have implemented a statewide monitoring program,
and 11 states along with the U.S. territory of Guam have enacted legislation to establish
PDMPs, but are not fully operational as of October 2011 according to the The Alliance of
States with Prescription Monitoring Programs (ctd. in USDOJ 2011), which advises and
informally oversees the implementation of such programs. A total of 48 states have
operational or nearly operational PDMPs. Wisconsin, where the present study was
conducted, during the duration of data collection did not have a functioning PDMP, but
was one of the 11 states with legislation in place to support the formation of one.
Despite the success the organization has had in proliferating PDMPs across states,
their implementation has received significant criticism. A recent article in the Journal of
the American Medical Association asks, “Can Prescription Drug Monitoring Programs
Help Limit Opioid Abuse?” Authors Gugelmann and Perrone note the lack of uniformity
in the implementation and design of PDMPs as a major obstacle to their effectiveness in
curbing opiate abuse trends. Some programs are available to clinicians, while others are
limited to law enforcement. Some states enable real-time updates after a prescription is
dispensed, while other programs update only periodically. Additionally, limited
communication between states’ PDMPs do not protect against patients who may cross
state boundaries to acquire prescriptions, which is of particular importance to
Northeastern states and areas or cities located close to state borders such as Milwaukee
and Northeastern Wisconsin.
Professionalization of Pharmacy. The field of pharmacy offers a productive site
for generating new conceptualizations of prescription drugs. Research to date has
predominately been focused on prescribers likely because physicians have greater
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authority and professional autonomy in writing prescriptions relative to other medical
professionals. However, research investigating the role of pharmacists in smoking
cessation has long proven these paraprofessionals can be effective producers of change in
the public’s consumption patterns of addictive substances (Zillich, et al. 2012). In
addition, pharmacists expansive training in pharmaceuticals both in the academic and
praxis spheres makes them important conduits for the cultural significance and roles of
such medications. Given the unique epidemiology of prescription drug abuse, knowledge
of the deeper significance of pharmaceuticals in society may bear on the nature of this
problem and perhaps few professionals are involved so wholly in the medications
dispensed to the public than pharmacists. Thus, the notion that a study of pharmacy to
uncover the significance of drugs and addiction in society is rooted in prior research and
while it reasons pharmacists may be capable to positively impact the quickly increasing
trends of pharmaceutical abuse, no studies to date have analyzed how pharmacists’
operate under new constraints imposed by prescription drug abuse.
Pharmacists have become increasingly important, as the repertoire of drugs on the
market has expanded exponentially over the course of the modern age. Accordingly,
pharmacists have been subject to an expansion in training from a four-year degree to a
six-year PharmD degree (American Association of Colleges of Pharmacy 2013). Despite
these new requirements, the number of accredited pharmacy schools swelled from 72 in
1987 to 128 in 2012 (Brown 2013). While new practice settings emerge for pharmacists
working alongside doctors to develop pharmacotherapeutic treatment regimens, research
showing pharmacists’ effectiveness in smoking cessation is encouraging for the
professionalization of an oft-forgotten discipline (Zillich, et al. 2012). Furthermore,
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according to Gallup polls dating back to 1981, pharmacists are consistently ranked the
most or second most trusted professional and their rates of trustworthiness have steadily
increased since the poll’s inception; the percent of the public saying their trust in
pharmacists is “high/very high” currently sits at 75 percent, second only to nurses with 85
percent and a healthy 5 percent above medical doctors (Gallup, 2012). Altogether, these
data paint a promising picture for the capacity of pharmacists to positively impact
healthcare.
The lack of attention paid to pharmacists in the literature is not surprising given
their lower status as paraprofessionals relative to physicians. Eliot Freidson is perhaps the
most well known chronicler of the sociology of health professions. In his seminal work,
Profession of Medicine (1974), Freidson lays out the characteristics imputed to
professionals including, “a formal standard curriculum of training, hopefully at a
university. They create or find abstract theory to teach recruits. They write codes of ethics.
They are prone to seek support for licensing or registration so as to be able to exercise
some control over who is allowed to do their work” (76). While paraprofessionals,
including pharmacists, may obtain all the trappings of full professionalization, as
Freidson notes the defining factor of professionals is autonomy. Freidson states, “while it
is legitimate for [paraprofessionals] to take orders from and be evaluated by physicians, it
is not legitimate for them to give orders and to evaluate physicians. Without such
reciprocity we can hardly consider them the equals of physicians” (76). It is, however,
difficult to imagine individuals, particularly trained in a field, complicit in or entirely
limited by this subordination. My research further illumines the ways in which
pharmacists as paraprofessionals find agency in their role marked by low professional

	
  

	
   20	
  
autonomy. Specifically, I hope to further build on Freidson’s exploration of the
boundaries and qualities of paraprofessionals vis-à-vis prescription drug abuse.
Addiction and abuse: Connotations and history. The term “addict” emerged in the
sixteenth century from the Latin words addictus, as the past participle of addicere
(dicere= to say; to adjudge or allot; assigned by decree; Oxford English Dictionary 2013).
Although now long defunct, this interpretation of the word survives in the colloquial way
in which the word “addict” is moralizing and often socially prescribed. Awareness of the
pejorative use of the term led professional organizations such as the American Psychiatric
Association who composes the Diagnostic and Statistical Manual currently in its fifth
iteration, to use the diagnostic term “substance dependence” (2013). Nonetheless, the
phrase “substance dependence” preserves certain connotations of the word “addiction” in
how denial is frequently utilized to describe this state, i.e., substance abuse and addiction
are rarely self-assigned descriptors, rather they are assigned by friends, family or the
public at large and an individual’s protestations and failure to absorb the term are recast
as denial.
Today, substance dependence in its many iterations is characterized as a disease
state. However, this notion dates back to 1878 with the invention of the hypodermic
needle making a form of opium and precursor to heroin prevalent at the time an injectable
and potent medicinal (Parssinen & Kerner 1980). Concerns about new trends in the
behavior of those prescribed the treatment culminated in a full disease model of addiction
in 1910. The fact that increasingly the drug was spreading out of the formal, mainstream,
medical sector and becoming comingled with other illegal and immoral behavior of the
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time, the fringes of society, as well as to minorities and immigrants hastened a new era of
drug policy and regulation (Acker 2002:2-9).
As suggested already, medicinals and illicit drugs have long shared a fluid and
constantly shifting boundary. Heroin, cocaine, and amphetamines were once used to treat
an array of health complaints, but are now strictly relegated to the black market. As the
pharmaceutical industry gained traction in the world market and the emergence of new
drugs quickened continually since the 1950’s, it is hardly surprising the number of legally
prescribed medications with an abuse potential continued to rise. The rate of prescription
drug abuse first was reported on by the popular Monitoring the Future prevalence study
administered by the NIDA in 2002. Since then, reported rates of Vicodin abuse have
steadily increased from 2.5 percent to nearly 3 percent (2012). Although not initially
impressive, declining rates of other illicit drugs suggest prescription drug abuse is
increasing, while steadying national averages of all illicit drug use. Increasingly,
individuals with problematic use of Vicodin or OxyContin are being introduced to a new
line of pharmacotherapeutic treatments in the form of buprenorphine, naloxone,
Suboxone (which combines the two), or Vivitrol. Such treatments have slightly different
mechanisms of action but are promoted for their ability to supposedly decrease craving
and/or inhibit the effect of opiates on the central nervous system. Criticisms abound
regarding the safety of such medications and the irony of treating prescription drug abuse
with prescription drugs of questionable safety and efficacy is not lost on a variety of
researchers and practitioners (Bazazi 2011, Gwin Mitchell et al. 2009, Meyers, 2013).
Addiction-as-disease is understood by two main processes: tolerance and
withdrawal (American Psychiatric Association 2013). Tolerance refers to an individual
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needing more of the drug to achieve the same effect; while, withdrawal is the presence of
adverse symptoms at the discontinuation of the drug. A proliferation of articles of the
biomedical perspective explore the neurochemical and neurological mechanisms of these
processes, but also serve to legitimize the diagnosis and the professionals that dispense
these labels and the medications that both cause and presumptively treat this affliction.
What is not captured in this simple yet complex, modern yet archaic concept of addiction
is how such shifting definitions of what is and is not addicting impact the professional
lives of those entrusted with the health and care of the public, particularly as the divide
between legal and illicit drugs vis-à-vis prescription drug abuse ever blurs these
boundaries.
Medicalization and pharmaceuticalization. Medicalization is widely researched
phenomenon describing the process whereby human conditions become treated as
medical conditions. Within the context of the history of addiction, medicalization is most
obvious in the shift from addiction as a personal moral failing and the emergence of the
disease model of addiction. The move has fueled a variety of medically-oriented
treatment regimens, both psychotherapeutic as well as medicinal. Twelve-step programs,
for instance, heavily rely on the notion of addiction as a disease. In the group reading
entitled “Why Are We Here?” read at the beginning of each NA meeting, the
organization explicitly states their stance on the status of addiction as a disease. “After
coming to NA, we realized we were sick people. We suffered from a disease from which
there is no known cure” (1986). Those intimately involved with addiction recovery
adhere strictly to this thinking as it removes much of the blame inherent in the idea
medicalization replaced—addiction as willfull deviancy resulting from deep, personal
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failings. Although stigma predicated on this thinking continues in the collective
consciousness as supported by decades of the “War on Drugs” and increasing minimum
sentences for drug crimes, medicalization has nevertheless been a powerful counterforce.
While detractors of medicalization note its overuse (Kleinman in Bell & Figert,
2012), the concept of pharmaceuticalization, a related but distinct term, have emerged to
describe the treatment of an aspect of the human condition by pharmacological agents
(Bell and Figert 2012:776). The paradigm is useful in analyzing both the proliferation of
treatments such as Suboxone to treat addiction to Vicodin or other prescription opiates, as
well as the growth of the illicit market for prescription opiates for abuse. Complimentary
to pharmaceuticalization from the perspective of consumers, is its effect on the move of
pharmaceuticals from the prescriber to the pharmacy and into the increasingly eager
hands of the public. Additionally, how the phenomenon actively shapes the definition of
addiction within formal, professional spheres and influences decision-making among the
only professionals to physically handle pharmaceuticals is a gap in the literature the
current study hopes to address, at least in part.
Theoretical framework. Since legal actions, such as those taken against
GlaxoSmithKline in New York by then Attorney General Eliot Spitzer in the spring of
2004 (People of the State of New York v. GlaxoSmithKline 2001), and the Vioxx
controversy wherein Merck voluntarily withdrew the osteoarthritis drug from the market
after evidence showed it significantly increased heart disease and stroke, increased public
and academic attention has been paid to medical ethics as they pertain to the
pharmaceutical industry. Several authors and researchers have uncovered the abuses of
the medical industry by pharmaceutical companies.
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One such work by Howard Brody (2007), professor and director at the Institute
for the Medical Humanities at the University of Texas Medical Branch at Galveston,
describes how medicine is “hooked” on the pharmaceutical industry in two ways. He says,
“in one sense, medicine’s relation to the pharmaceutical industry, and the gifts and
rewards that it dispenses, has been likened to an addiction. Addiction has been called the
“disease of denial,” and we will see that denial characterizes many aspects of medicine’s
assessment of this relationship” (5). Brody’s book gives a thorough analysis of
medicine’s betrayal of public trust for the money and funding provided by
pharmaceutical companies. Brody’s work focuses on what he calls the “industryprofession interface,” or the relation of the pharmaceutical industry to the physicians who
often receive funds to garner research aligned with the pharmaceutical industry’s goals
and prescribe these medications and the Food and Drug Administration (FDA) who is
charged with regulating prescriptions. However, Brody explicitly shies away from
speaking to the industry’s relation to society at large, or drawing specific parallels
between the way addiction is characterized on an individual level to the medical system’s
relation to drugs: namely, what logic predicates the role of such denial in addiction? The
emergence of prescription medications away from therapeutic agents and towards drugs
of addiction makes this question of particular import to studies of addiction, as well as the
medical industry. Lastly, Brody’s work and other work critical of the pharmaceutical
industry’s role in medicine makes it possible to ask: what parallels may exist between
individual-level addiction and the flow of medications out of the pharmacy and into the
public’s hands in a lived, real-world context?
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From an economic perspective, Kalman Applbaum (2010) explores the
perception of the side effects of Zyprexa in the drug’s expansion to the Japanese market.
He describes the “shadow science” used to downplay and recast the harmful side effects
of the drug and manipulate prescriber’s interpretation of these effects to facilitate such
expansion. Applbaum makes clear how pharmaceutical marketing influences prescribers;
however, an interesting question that arises from his work is: how expansive is this
influence? Is it possible those that rarely come in direct contact with pharmaceutical
company marketing and have limited decision-making power have similarly been
subsumed by the a “shadow culture” that insists on casting pharmaceuticals as universal
forces of health? Michael Oldani (2004) similarly analyzes the implications of the
pharmaceutical market from a global-economic perspective, but combines his analysis
with a personal-psychological interpretation. He notes, “pharmaceutical companies are
quick to promote to doctors (and to the general public) that the patient’s best interest is
always being served with the introduction of new medications” (338). Again,
pharmaceuticals are pushed as unqualified agents of health, in this case, explicitly to
prescribers and the public at large. While ostensibly extolling the value of
pharmaceuticals with the patient’s health in mind, the discourse of pharmaceutical
marketing both on an international and interpersonal scale actually serves to further a an
inherent logic to meet the industry’s (versus the patient’s) needs. As Applbaum notes on
the global distribution of pharmaceuticals, the reason for which he gives as “because their
output is held to be the fruit of medical and pharmaceutical science, which operate on
universal principles and whose importance is acknowledged everywhere. The global
distribution of medicines carries the legitimating force both of science and ethics, insofar
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as the speedy delivery of drugs to the sick is an unquestioned good. Good medicines
should ‘sell themselves’ insofar as their utility need not be argued” (236). The same logic
predicates the distribution of medicines in an interpersonal relationship, as between a
doctor and patient, or pharmacist and patient, as the sphere of the global and local
contexts of pharmaceuticals are difficult and possibly lack utility in being disentangled.
At another end of the chain from pharmaceuticals to consumption, Paul Brodwin
(2010) analyzes front-line clinicians in community psychiatry who must actively
negotiate compliance to pharmaceuticals with patients at the edges of society. Brodwin
describes the “assemblage of compliance” composed of the competing interests of case
managers and patients as mediated through an array of physical artifacts of great
theoretical and practical import, including the container that separates patients daily
medication allotments (termed a “med cassette”), paperwork, medical supplies, and
treatment order. Compliance is then cast as micropolitics between the constrained
position of both the caseworker bound by policy and law, and patients bound by their
own low social status and as recipients of care. Taken together, Brodwin, Applbaum, and
Oldani share a common theoretical root in Bruno Latour’s Actor-Network Theory (2005).
Be it data on the side effects of a pharmaceutical product, a “gift exchange” that
facilitates a multi-billion dollar global economy through personal exchanges, or a “med
cassette” exchanged between a case worker and patient, the threads connecting and
interweaving all the components of how medications are produced, sold, exchanged, and
consumed often between two highly constrained positionalities actively construct a
dialogue regarding the role of drugs in society.
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To this dialogue, I hope to add a voice often so lost in the milieu it frequently
goes unnoticed and arguably taken for granted—the participatory role of those that
dispense a pill at the injunction of a doctor’s prescription pad. Pharmacists constitute a
key role in the exchange of pharmaceuticals from their production and sale as part of a
corporate structure, mediated through company representatives to prescribers, from those
that have the authority to grant permission for patients to access these products, to the
actual consumption of such medication by patients. Pharmacists also represent one of the
most accessible components in the system. Frequently located outside clinics or hospitals,
in hubs of business and economic activity within the community itself through
employment in corporate pharmacies, pharmacists take no appointments and sometimes
work third shifts in 24-hour pharmacies while other medical establishments are closed.
While pharmacists swell in numbers (a 60 percent increase since 2000 according to
Brown, 2013), are generally are not targeted by pharmaceutical company reps, and have
little autonomous decision-making power, it is curious to ask: have pharmacists absorbed
the dialogue that characterizes the wider exchange of pharmaceuticals? What would this
dialogue and these negotiations and micropolitics as lived in a real-world, daily practice
look like? These questions grow ever more pertinent as prescription drug abuse rates
continue to soar, continuing to blur the line between licit and illicit and call into question
the use and role of certain classes of abusable pharmaceuticals. Furthermore, prescription
drug abuse becomes a site in which the patient-care centered dialogue of medicalization,
which ultimately seeks to provide care for whatever comes to be defined as an ill, collides
with the pervasiveness of pharmaceuticalization, a trend characterized by the profit-

	
  

	
   28	
  
generating work of multinational corporations whose products increasingly define
medical care across the globe.
Conclusion. Prescription drug abuse constitutes a problem of growing concern for
medical professionals and communities. The abuse of pharmaceuticals for non-medical
purposes shares similarities with, but sharply diverges from the abuse of classically illicit
drugs. While measures such as prescription drug monitoring programs (PDMPs) seek to
more clearly define the boundary between licit and illicit use, a history of social theory
predicates inquiry into the role of similar technologies, including the medicines
themselves, as Latourian artifacts. Historical precedents establish “addiction” and its
descendent term “substance dependence” as social designations and constructions as
much as diagnoses. Pharmacists represent a under-researched but potentially fruitful site
of inquiry into how a descriptor such as “addict” become encapsulated in a medicalized
and pharmaceuticalized discourse, how these terms are absorbed by the fringes of
medical society, as well as the iterative process by which these new but familiar
micropolitics shape the paraprofessional role of pharmacists.
The way in which those medical professionals that deal most directly with the
medications themselves in the script-for-pills exchange absorb the logic of
pharmaceutical marketing has great import for the evolution of pharmacy as a profession,
the prescription drug abuse epidemic, and wider sociological thought on the role of drugs
in society. The logic underpinning the work of pharmaceutical corporations, prescribers,
caregivers, and the healthcare system is becoming increasingly entangled as care
becomes directly synonymous with medication. The consequences of these developments
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and thinking, while buttressed by existing literature, are currently unanswered, yet
constitute a useful and extremely pertinent investigation.
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Chapter III:Methods
Anthropology is a science unique from other disciplines in that meaning is
interpreted from human experience and the a priori assumption that an absolute truth
exists is abandoned in favor of personal, relative truths. Clifford Geertz’ famous quote
proves quite apropos decades after its composition that “man is an animal suspended in
webs of significance he himself has spun, I take culture to be those webs, and the analysis
of it to be therefore not an experimental science in search of law but an interpretive one
in search of meaning” (1973: 5). As an undergraduate student in anthropology and
psychology, I did not fully appreciate the wisdom and perspective of this quote until I
undertook my first truly anthropological research assignment my first semester in
graduate school. While immersing myself through participant observation of Narcotics
Anonymous groups and interviews with recovering addicts, I was able to fully embrace
the utility of an interpretive approach to meaning. While biomedicine strictly adheres to
the idea of addiction as a biological disease, I discovered those who struggled with
addiction found strength and power in their personal psychological victories in
overcoming substance abuse. While literature on addiction readily casts addicts as
victims of a drug’s power over their thinking and behaviour, in fact, the recovering
addicts I came to know as a result of the project relayed their agency in both their drug
use and recovery.
I remember quite clearly meeting with one interviewee and my experience
cemented these personal views. I had known this individual for a few months and was
grateful he had agreed to meet with me. We met to conduct the interview and before I
could formally begin, he said he had some questions for me. He wanted to know my
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opinions on addiction and Narcotics Anonymous as a recovery program. I explained to
him I was not concerned with deciding whether NA was effective, but, accepting its
efficacy, why it was effective from the perspective of those who had found success in the
program. He was further comforted by my admission that while I was “the researcher”, I
privileged his knowledge and experience with addiction and recovery over the
professional literature; I was hoping he could educate me about his experience, not match
the legitimacy of his words to the objective truths extant in the literature. He was candid
in his interview and his candor throughout gleaned some of the most useful data for the
project. I came to understand that allowing the voice of those with native knowledge of
addiction to be heard in the “Ivory Tower” of professional literature was both an ethical
and methodological imperative.
Anthropology is unique from other disciplines in yet another way. The
positionality of the researcher as both a producer and reproducer of data comprises a
central way anthropology recognizes and embraces bias, instead of attempting to reduce
it in the pursuit of objective truth as is the case with positivistic science. Renato
Rosaldo’s admission that his understanding of headhunting among the Ilongot was
limited before the grief brought on by his own wife’s death allowed him to connect with
the practice more deeply is a widely familiar example of this practice (1980). Similarly,
my positionality growing up with prescription drug abuse has informed my research and
perspectives and my story has intimately directed the undertaking of my research. One of
the most poignant memories of my childhood was finding my father’s cache of
prescription bottles and baggies of white powder under his bed. I was confused at the
time why several of them were not in his name, but the memory stuck with me and as I
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witnessed friends begin using drugs, I came to understand why my father would fall
asleep at odd times of day juxtaposed with extreme bouts of energy. I became estranged
from my father early in my adolescence as he slowly slipped out of my life. In first
undertaking this research, I felt a profound connection with a side of his life that always
remained remote from me.
After completing my fieldwork and in the midst of writing my research, I was
informed of my father’s death from a heart attack. Like Rosaldo, my struggles with
experiencing the grief of my father’s loss made my subject alternatively cathartic and
emotionally raw and deepened my experience with the subject of prescription drug abuse
and addiction. Although I spoke with and observed pharmacists, I was grateful for their
constant sensitivity to patients who struggled with abuse. They did not see their labor as
separate or even parallel from the experience of addicts themselves and it was important
for me personally and for the integrity of my analysis to translate this same holistic
perspective to my labor. While researching drug abuse history and modern trends, I
undertook the personal project of researching my father’s life and the years of life I had
not been privy to. I was able to learn he kept the history of his use a secret from his
family. I have similarly struggled with how to express being the daughter of a drug
abuser—the fear of the halo of his drug abuse encompassing me and others’ perception of
me, my similar unwillingness to be seen in the light of the substances whose power and
voice seem to echo louder than the people who use them. Thus, the stigmatization of drug
abuse and the power of substances through their social construction to connect and tear
apart familial and professional structures was not an experience-far topic, but rather a
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process I was actively swept up in along with the pharmacists whose lifework had been
similarly altered in response to prescription drug abuse.
I suspect for these reasons, my analysis differs from other research on the topic.
The aspects of the problem my personal encounters illumined and alternatively, the
nuances my biases left me blind to color my perspective in ways I anticipate and in other
ways I cannot. Far from a limitation, I prefer to view this analysis and the problem of
prescription drug abuse itself as a human construction, as living and evolving as those
that shape the nature of this problem everyday. My primary aim as both a person affected
by and researcher of addiction is to allow the evolution of this problem, the policies and
countermeasures adopted, to be directed by the real-world lived experiences of all the
actors involved through the research I view as most ethical and most sound. Thus,
contributing the experience of pharmacists with regards to this problem became an
essential undertaking. As can be expected, the ways I describe my personal experience as
intertwining with my research subject is far from complete.
My four-month excursion in the field began in early 2012. Preliminary research
into the literature on prescription drug abuse produced limited gains, as the body of
literature then much as now is largely relegated to epidemiological description. My
search for literature analyzing the profession of pharmacy produced an equally narrow
range of literature. Thus, I decided to begin my experience the same way pharmacists do,
in a pharmacy education program. I attended lectures and labs at a pharmacy school in
the upper Midwest for approximately three months. I was immediately shocked by the
difficulty in engaging a bureaucracy for fieldwork in comparison to an organization such
as Narcotics Anonymous. Unfamiliar with the methods of anthropological research,
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department heads were immediately suspicious of my presence. Despite my entreaties
that my intentions were legitimate and going through the proper channels of Institutional
Review Board Approvals for both my institution and theirs, they quickly limited my
access. My initial entrée into the institution via a faculty member proved a constraint, as
my observation took place in a different department. I became aware a professional
competition existed between the faculty member I initially made contact with and the
department chair in whose department I ended up conducting research. In no uncertain
terms, the constraints of my fieldwork were tightened. I was strictly disallowed from
communicating at all with students, but was allowed to attend lectures, audio record them,
and attend labs under the supervision of another faculty member.
While I had originally intended to conduct interviews with students, this option
was quickly tabled and I sought interviews with current practicing pharmacists. Through
mutual friends, I connected with a number of pharmacists ranging in level of experience,
setting, and background, including pharmacy students of a third institution. The
experiences they shared constitute the majority of the data presented herein. Some
pharmacists early in their career took special care in their presentation. One made it a
point to tell me he wore a suit that day to work in order to look more professional for our
interview. I noticed the older and more experienced pharmacists had no such pretences.
They chose to meet in more informal settings, showed up in jeans and t-shirts, relaxed in
their seats and were candid and quite frank about the limitations they operated within on
the job and their frustration in dealing with patients and doctors. Regardless of the level
of experience or setting a particular pharmacists practiced in, certain themes and
contradictions regarding patients and prescribers emerged early and are presented herein.
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Chapter IV: Pharmacists and the addicted body
Prescription drug abuse receives increasing attention from researchers,
policymakers, as well as mass media. Entangled in these multiple discourses are larger
beliefs about drugs, the medical system, and the body. While the role of doctors in
patient’s acquisition of controlled, abuse-able drugs is more frequently profiled, scant
attention has been paid to the professional roles of pharmacists and how their
conceptualization of drugs, the medical system, and the body can enlighten the debate
concerning prescription drug abuse.
Pharmacists can be classified as paraprofessionals (Freidson 1974:71-84). Their
work does not entitle them to an equitable amount of agency and autonomy as that which
characterizes the work of more prestigious medical professionals. The expansion of
available drugs on the market has coincided with an expansion on the degree
requirements of pharmacists. Where a four-year degree once was sufficient to run a
pharmacy, these jobs are relegated to holders of a six-year Doctorate of Pharmacy degree
(PharmD). Pharmacists may elect to pursue an additional two-year residency requirement
that enables them to practice in hospitals and other settings where they are involved in
direct patient care (American Association of Colleges of Pharmacy 2013). Yet, the vast
majority of pharmacists will be employed by corporate pharmacies where patient
interaction is brief and they frequently describe succumbing to pressure from corporate
superiors to increase profits. Thus, pharmacists’ work is segmented into two discrete
roles. On one hand, they share the care-oriented goals of other medical professionals
aimed at patient care. On the other hand, however, pharmacists also experience a productoriented ethos akin to business.
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Traditionally, pharmacists dispense medications such as antibiotics that treat
biomedical conditions. In dispensing these types of drugs, their business ethos are in
harmony with the medical ethos of patient care. Dispensing the drug (profit) will improve
the patient’s health (care). However, the growth of pharmaceutical companies has
introduced new classes of medications to treat a variety of newly defined illnesses.
Among these new pharmaceuticals are a mélange of medications with abuse potential.
According NIDA (2011), chief among these abusable medications are Vicodin,
Oxycodone, and stimulants used in the treatment of ADD/ADHD such as Ritalin and
Adderall. With the growing attention prescription drug abuse has received in recent years,
pharmacists are acutely aware when dispensing these drugs of the possibility they are
dispensing an illegitimate script. An illegitimate script1 may include a fraudulently
altered script, a script for medication the patient intends to use for the purpose of “getting
high” or divert through selling the medication to addicts for the purpose of “getting high”.
When the possibility for abuse exists, the situation brings into conflict several aspects of
pharmacists’ work and the ethos that direct such labor.
This chapter will focus on first describing the nuances of pharmacists’
professional ethos and self-described professional roles and how pharmaceutical abuse
brings several aspects of their work into conflict. While their business ethos stress
dispensing a product in order to increase profits, pharmacists’ care ethos dictate
dispensing an addictive agent to an addict is not regarding the patient’s well-being and
health. Additionally pharmacists describe their role on one hand as “drug experts”
	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
1	
  For clarity, I will use the term script to refer to the physical paper patients receive from
their doctor and bring to the pharmacy with indications for how the drug should be filled.
I will only use the term prescription as synonymous with medication to refer to the bottle
or pills patients consume.	
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conducive to a business ethos. Yet, they also describe their professional role as being
patient advocates. The latter reflects their care ethos. Pharmaceutical abuse similarly
brings into conflict these two professional roles. I will argue pharmacists partially
ameliorate these role and ethical tensions by employing a particular understanding of
drugs and addiction. This conceptualization sees drugs as agents of fragmentation where
the addicted person is split into the addict on one hand, and the ‘true patient’ on the other.
The process of addiction is seen in this conceptualization as enshrouding the ‘true patient’
beneath the cloak of addiction and enables pharmacists to navigate the uneven terrain of
being paraprofessionals straddling business and medicine, profit and care.
Business versus care ethos. A pharmacist working in a corporate pharmacy in a
small community somewhat notorious amongst medical professionals in the region for
prescription drug abuse discussed with me the “business side” of pharmacy.
“[Pharmacies] will be more successful the more scripts they sell, so pharmacies are trying
to encourage more script volume…that means more revenue, better business.” Another
pharmacist described how he has “to be more efficient. It used to be you could be
profitable doing with one pharmacist and a tech, you’d only need to do about fifty scripts
a day. Now, you need to do about 200 scripts a day in order to be profitable.” He went on
to more specifically detail how his previous corporate pharmacy stopped filling for
certain medications because “we are getting negative margins meaning we are losing
money on certain scripts that we used to make money on…” Pharmacists experience the
demand for increased script volume most acutely in their workflow. Pharmacists come
under increasing pressure to work faster without sacrificing accuracy. However,
“accuracy” is frequently couched in economic terms. “At one point, the average mark-up
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on a script was about two percent meaning after we pay our people, after way pay the rent,
all your overhead, it’s two cents on the dollar. So, you make a mistake on a $100
medication or a $1,000 medication, you are taking a pretty big loss.” Thus, the cost of
poor accuracy and efficiency is lost revenue. Losing revenue is antithetical to the
definition of “good business” proffered by pharmacists. One pharmacist described the
workflow in retail as unstructured, “all of a sudden rush hour comes along and it’s just
book, book, book, you go as quick as you can and be as efficient as you can.” Where the
business of pharmacy dictates increased script volume, pharmacists experience
unstructured workflow where their accuracy and job performance is judged by the effect
on revenue. Pharmacists’ “business ethos” is centered on the profit-generating aspect of
their work and position the individual as a customer, not a patient.
Business ethos: Pharmacists as drug experts. I have described pharmacists as
paraprofessionals equally engaged in a set of ‘business ethos’, which essentially productcentered, while also engaging in a set of ‘care ethos’, goals aimed at patient-care. These
ethos are not discretely practiced by pharmacists on the job; rather, these two ethos are
frequently conflated. Pharmacists express their aim of patient-centered care their selfidentified role as “drug experts.” The way in which this role helps to form pharmacists’
“business ethos” must be developed here. Kim and Will are pharmacy interns I met in a
bustling coffee shop in a mid-size Midwestern city. Both had been exposed to pharmacy
for several years: Kim’s cousin runs an independent pharmacy in Minnesota and Will
began as a clerk in high school at his local pharmacy. When I asked them what role
pharmacists have in healthcare, Kim responded immediately, “The drug experts. We may
not know how to diagnose. I guess we’re tested on it and we’re exposed to it, but that’s
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not what we learn. You learn they got this; this is what you treat. This is their renal
functions, this is what drug dose to use.” Will agreed and added, “not just necessarily
treatment. It’s these deeper, more meticulous, more specific things like the drug lasts
eight hours in the body, so we gotta dose it every eight hours not every twelve.”
Pharmacists’ role as drug experts supports the revenue-focused aspect of their work, as
well as the patient- and care-oriented aspects of their labor. On one hand, their role as
drug experts extends to patient counseling. The pharmacists I spoke with who practiced
in independent pharmacies stressed how their role as drug experts was enacted to help
patients find the cheapest, most effective medicine. One example an independent
pharmacist I spoke with provided was encouraging patients prescribed Prevacid, an antireflux drug, to talk to their doctors about Tagamat or Zantec, which are significantly
cheaper. Thus, pharmacists’ role as “drug experts” reinforces their goals of patientcentered care.
Yet, their knowledge of medications offers a way to legitimately participate in the
hierarchy of medicine and intersects with the business-oriented nature of their work as
well. In speaking with Will and Kim, the pharmacy interns, Will was careful to correct
Kim when she cited the higher authority of doctors in prescribing medications. He
retorted, “Well, sorry, they’re the ones prescribing [the medications] but we’re the ones
verifying whether or not they’re appropriate.” Kim quickly tried to cut in, “I realize that,
but…” before Will jumped in, saying “It still has to go through us.” Through pharmacists’
knowledge of drugs, they are able interact with doctors in a meaningful way by either
allowing their scripts to be filled or questioning the doctor’s decision making. Thus, in
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enacting their role as “drug experts” pharmacists can simultaneously be product/business- and patient-/care-centered.
Care ethos. However, pharmacists as paraprofessionals also share characteristics
in common with medical professions, not only with business. Pharmacists are invested in
their patient’s health and well-being like other medical professionals. Pharmacists also
couch their work in terms of patient care. When engaging in this script, the individual is
treated as a patient. One pharmacist I spoke with described enacting his role as a medical
professional: “we see the patient/customer the most frequent of any healthcare provider. I
think considering the fact that people are trusting us, they are going to take something
that we are giving them and putting it in their mouths and bodies to regulate a condition
or to help try to maintain health.” In addition to how this pharmacist was acutely aware of
his connection to patient health, he was also explicit of how the individuals he helps are
both patients in the medical system and customers of a business. While community
pharmacists were the only ones to couch their work in these terms, which will be
expounded upon in a subsequent chapter, all the pharmacists I spoke with were motivated
to enter pharmacy for patient care and relayed stories to me with pride about instances of
patients approaching them with questions about their diagnosis or about complementary
non-medication interventions. All pharmacists expressed a desire to develop relationships
with patients. Pharmacists’ orientation toward patient care constitutes what I call their
“care ethos” which simultaneously guide their on the job decision making along with
their “business ethos” detailed above.
Care ethos: Pharmacists as “patient advocates”. Similar to their role as “drug experts”,
pharmacists describe themselves as being “patient advocates”. Pharmacists experience
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the care aspects of their work through the hierarchical nature of the medical field. The
fact that prescribing physicians have more prestige, status, and professional autonomy is
reinforced throughout pharmacy curriculum. In one of the labs I observed, students were
evaluated on their ability to confront a professor acting as a prescribing physician who
has made a mistake on a script. Students, acting as pharmacists, were given a patient
description and the doctor’s script and had to identify the mistakes on the script, which
could range from a dosing error or an inappropriate drug for the “patient’s” condition.
Students who scored high marks on the lab were commended on their deference to the
physician’s authority and providing research gathered from textbooks or PubMed to
support their suggestion. Once these students enter practice, they likely will have to
respect the hierarchy in several ways as the practicing pharmacists I interviewed
described.
The burden of doctors to increase their patient load and the decreasing amount of
time doctors have to spend with each patient is well documented (Dugdale, Epstein, and
Pantilat 1999, Baron 2010). However, how the demand for doctors’ time intersects with
the role of pharmacists in the day-to-day practice of pharmacy is not as well understood.
As mid-level practitioners with little to no authority within the medical hierarchy,
pharmacists rely on prescribers’ authority heavily and in multiple capacities. The most
pervasive demand for doctors’ time from pharmacists is in checking suspicious scripts.
However, pharmacists frequently bemoan the inaccessibility of doctors. One pharmacy
intern described contacting physicians: “So, you call [doctors] and you know all of a
sudden ‘Oh, I’m with a patient.’ So, they’ll call you back. Well, what do you tell the
patient that’s standing right in front of you? ‘No, you can’t have your medication right
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now?’” Pharmacists must get physician approval for anything on a script that is not clear
or to make any change to a script. They lack the professional autonomy to do so and also
are encouraged by their companies to shift the onus of (legal) responsibility on physicians,
including in instances of suspected fraud. One pharmacist who managed a corporate
pharmacy in a small town told me she “[knows] for a fact that [Corporate Pharmacy X]
doesn’t allow us to call the police or anything. We have to call the doctor and the doctor
has to initiate that sort of thing.” Similarly, pharmacists avoided confronting patients and
prefer to notify the doctor of a problem script to allow them to rescind the script. One
pharmacist told me how “I try not to deal with the patient as much as I can just because
ultimately the doctor needs to be involved.” If they cannot get a hold of the doctor,
pharmacists will defer to other entities with professional autonomy in order to decline the
patient’s script. One pharmacist described how she has run into “house fires…where
patients said they had a house fire and they lost everything but they are only looking for
their narcotic again even though they have diabetes medications, hypertension medication
and depression medication.” In one such case, the pharmacist researched online to find a
house three doors down from the patient had burned, leaving the patient’s house
unscathed. “I called the insurance company and so I wasn’t technically lying to her and
they said that they would give her diabetes medications and her hypertension
medications…and the narcotic they said they wouldn’t really do much to help her get
through.” The hierarchical nature of pharmacists’ work is another aspect of their
orientation to care over business where they are beholden to the authority and autonomy
of prescribing physicians or insurance companies in order to conduct business. Thus,
pharmacists are highly constrained professionals through the medical hierarchy. These
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constraints define in part their orientation to other medical professionals and to care on a
broader scale.
Their second role as care-oriented patient advocates also treads the line between
pharmacists’ roles as businessmen and medical providers. A pharmacist who runs a small
town independent pharmacy had been a pharmacist the National Guard for twenty years.
She continued to live by the motto she learned in the military, “getting the right drug to
the right patient at the right time.” This slogan reinforces the simultaneous drug and
patient centeredness of pharmacists’ work. The first pharmacist I spoke with to identify
her role as “patient advocate” described this as “I’d say we are patient advocates. So, try
and help get patients the correct medications and also the best prices and ways they can
afford it, that’s everything. And also safety. Protecting a patient from themselves
sometimes whether they like it or not [emphasis added].”
The significance of the prior quote should be properly contextualized. The notion
that a patient needs protecting from himself or herself has great implications for
understanding how pharmacists conceptualize prescription drug abuse. In dispensing an
antibiotic, for example, pharmacist’s business and care ethos are in line. Selling the
medication simultaneously brings profit and health. However, prescription drug abuse
problematizes and brings into conflict these two ethos, as the patient’s acquisition of the
drug enables addiction, a harmful and detrimental state. How pharmacists ameliorate this
tension is what the remainder of this chapter will focus on.
Business and care ethos: Problematized by prescription drug abuse. A pharmacist
told me his professors preached to him to “treat the patient, treat the patient and make
sure that they are comfortable and happy and satisfied with the care that you give them

	
  

	
   44	
  
and make sure that you are helping them out the best way possible.” Yet, he observed a
“big discrepancy” between the “idealism” propagated in pharmacy school and the
realities of combating drug diversion. He soon found with regards to the patient dynamic
promoted in school “working and having real life experiences teaches you that that’s a
really bad philosophy.” He went on to describe how “you never want to turn someone
away if they have a real reason for needing something early, but you got to be cautious.
You got to realize that people are always going to lie.” Thus, pharmacists quickly
approach their practice facing two fundamentally different kinds of patients: one who
seeks to legitimately acquire medications for the treatment of a ‘true’ illness and another
who seeks to illegitimately acquire medications for abuse. In order to incorporate these
two patient/consumers and the ways in which they intersect and bring into conflict their
two ethos, pharmacists must re-conceptualize the nature of drugs and how they interact
with the patient’s identity. Then, pharmacists adopt the view that drugs fragment the
individual into the ‘true patient’ and the ‘addict’ in order to accommodate both their
business ethos and their care ethos.
How pharmacists conceptualize addiction. The way pharmacists discuss the
process of addiction is indicative of the conceptualization of drugs as fragmenting agents.
Pharmacists employed two terms to discuss the habituating effects of long-term
maintenance on drugs: dependence and addiction. Pharmacists describe dependence as
being both physical and psychological. Physical dependence refers to the processes of
withdrawal and tolerance. Withdrawal is defined as the onset of symptoms upon
discontinuation of the drug. The concept of tolerance refers to needing more of the drug
to achieve the same high, or effect. Psychological dependence is described as a separate
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but related process. Psychological dependence was described to me as a vague process
where “your mind just becomes fixated on ‘I need this drug; I need this drug’…their
body is fine but they’re just thinking, thinking, thinking about it.” The distinction
between a drug’s physical and psychological effects and the notion that “their body is
fine” but the addict’s mind is focused on the drug suggests a drug’s capability to create a
mind/body dualism. Although “addiction” is now the preferred term in the literature, the
term refers to the same constellation of phenomena as physical and psychological
dependence. Thus, addiction and dependence are understood as processes by which a
substance fragments the addict, separating mind from body as well as the autonomous
control of the mind over the body.
However, pharmacists carefully delineated dependence from the pejorative
connotations of the term ‘addiction’. One pharmacist pointed out how it is “hard to prove
someone is addicted versus in actual dependence. I mean, we know that with any
medication your body develops a kind of dependence over time. As far as drug abuse,
that is more of the psychological, that is the craving, the drug-seeking behavior, the ‘I’ll
do anything to get a fix,’ as opposed to the physical.” Thus, psychological dependence is
the element that delineates the more general term of ‘dependence’ from ‘addiction’.
Another pharmacist described “one guy, he gets Vicodin every Friday. We never allow
him to get it early. So, I say ‘No, you’re due Friday; you can come in Friday’ and of
course, he’s always there at 9 o’clock in the morning to get it, but he knows! We’re not
going to fill it early for him and we’re up front with him…Now, that’s a guy that
probably has a legitimate need for the pain medication but is very dependent on it. [He]
doesn’t want to run out.” Again, dependence is employed as a general term, not
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necessarily problematic, alternatively referring to a biomedical, physical process common
to many medications and an independent psychological state. Thus, the presence of
dependence does not necessarily make the prescription illegitimate. Dependence in the
presence of a legitimate health concern is viewed as an expected occurrence of long-term
maintenance on medication for a chronic condition. Addiction, then, can be defined as
primarily psychological and pursuit of the drug when it does not serve therapeutic goals.
A legitimate patient, the ‘true patient’, is one who “knows” they are dependent, as the
patient in the prior example who attempted to get his Vicodin early. The addict is not
aware of their dependence on the medication, meaning through the process of addiction,
pharmacists see the drug as splintering the individual’s biological processes from their
psychological awareness. For example, one young pharmacist in a small-town branch of a
corporate pharmacy told me about a patient he encountered early on in his career who
was picking up a prescription for Suboxone.
One time when I was first starting out a guy was picking up a drug called
Suboxone, which is a strip that dissolves under your tongue and it helps if you
become addicted to a pain medication. It just helps to provide a lower amount of
that feeling from the drug throughout the day it prevents you from really abusing
that drug or other pain medications and I was just kind of asking him ‘So, what
did the doctor tell you about this so far?’ Just trying to counsel him. It wasn’t too
busy, so I tried to have a good conversation. He seemed interested and everything.
He really wanted to know all about it. He said, ‘Well, it’s kind of a necessary evil
right now.’ And I said ‘Oh, okay I think I know what’s going on here.’ And he
says ‘Yeah, I was taking pain medications for my back and after awhile, I just
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realized I shouldn’t still be on these but it’s really hard to stop.’ So, that’s why he
was taking Suboxone. And then, we kind of went through what you can expect as
a result of taking Suboxone, all the risks you know. You can still be addicted to
this, but if you follow your doctor’s directions carefully and follow up with him
and gradually work your way off the Suboxone, hopefully you can get back to
normal before you get dependent on the [Suboxone]. [emphasis added]
The pharmacist described dependence as the result of not carefully following doctor’s
orders, following up with the doctor, and weaning off Suboxone. As described earlier,
dependence is referring to becoming physiologically habituated to the drug. Here, a
patient’s compliance and adherence is perceived to be indicative of the awareness and
will to discontinue Suboxone and other addictive agents. If these behaviors are not
followed, then the patient is deemed to be unaware of their addiction and not pursuant of
getting clean. Thus, addiction occurs in the absence of compliance, adherence, and hence,
awareness. Consequently, addiction is once again viewed as the result of a drug’s ability
to fragment an addict’s biological processes (the ‘true’ patient) from their psychological
awareness (the addict).
In review, as paraprofessionals, pharmacists are alternatively product- and carecentered. In order for these to not be in conflict, the product (prescription) has to be of
therapeutic value (treat a legitimate diagnosis). The patient’s awareness is what makes
the illness legitimate because awareness is the distinguishing element between
dependence, or becoming physiologically habituated on the drug, and addiction, where
awareness of dependency is lost. By viewing the addict as essentially two individuals-- a
biological customer and a psychological patient—the pharmacist can take their care ethos
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out of conflict with their business ethos. I will now describe this conflict and how this
understanding of addiction resolves the professional and ethical tensions that arise.
How ethos combine in pharmacists daily practice. Central to pharmacist’s on the
job decision-making is identifying the individual on the other side of the counter as a
‘true patient’ or an ‘addict’. If the patient is ‘legitimately’ in need of the medication,
pharmacists can pursue their business ethos in receiving the profit in line with their care
ethos in helping the patient treat his or her ailment. However, the ‘addict’ may be
physically dependent, but pharmacists view them as psychologically unaware of their
dependency. This division is what specifically concerns pharmacists about dispensing
drugs of abuse to addicts. While pharmacists are invested in increasing revenue for their
pharmacies in line with their business ethos, their care-ethos is brought into conflict.
Since the drug does not correspond to a ‘legitimate’ ailment, the drug is not seen as
having therapeutic value although it would ameliorate withdrawal and tolerance.
Pharmacists describe the difficulties and frustration in handling prescription drug
abuse from a highly constrained professional position. One pharmacist said it best when
he stated, “the problem that pharmacists have is we’re stuck in the middle. If it’s a
legitimate prescription…we’re hard pressed to say ‘No service.’” Another pharmacist
echoed a similar sentiment in saying, “more often than not, we end up getting stuck doing
things that we don’t feel comfortable with.” For the trained and well-intentioned
pharmacist, having to dispense to someone whom they do not believe to have full
awareness of the possible effects of the medication brings up issues of consent and causes
them to question whether they are delivering care although generating revenue and profit.
Thus, prescription drug abuse for pharmacists in a highly constrained position with low
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professional autonomy who straddle the boundary between business and medicine,
product and care, brings these two ethos and roles into conflict.
Pharmacists’ frustration appears in how they often handle patients they suspect of
abuse but who they are unable to take legal action against or refuse to dispense to.
Pharmacists often have difficulty in substantiating suspicion of abuse or diversion,
especially when overburdened doctors may take hours to return phone calls and
corroborate a prescription. So, pharmacists find other means to hassle patients suspected
of abusing or diverting medications as both an outlet for their frustration and an attempt
to find agency in their highly constrained professional position. One pharmacist described
his “poker face, the front of professionalism. ‘Oh, so sorry that you are in pain right now
but I need to make sure this leaves correctly, so please allow me a couple minutes to
make sure I can contact your doctor, get everything accomplished the way he wanted it
to.’” Pharmacists then will ask for supporting documentation, such as a driver’s license
that is not legally required. One pharmacist explained the utility of this approach because
“once you ask for the driver’s license, they’re just like, ‘Oh, it’s in the car.’ Then, they
don’t come back.” Other times, pharmacists ask the patient for specifics on medications
or medical equipment such as the volume and gauge of syringes, or simply insist on
speaking to the doctor over the phone before dispensing. One pharmacist described a
situation where he did exactly this.
“Sometimes, it’s just professional fun to mess around with them…there’s usually
different specifications to a syringe. What volume is needed? What guage and
what needle length? They’ll just make up absurd numbers…just stuff like that and
you toy with them…I just try to ask them questions and just make them answer
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me that they’re not using them legitimately. What kind of syringes do you need?
Oh, 300’s? Well, I need you to be more specific than that in order to sell those to
you.”
These examples clearly highlight the presence of the professional and ethical conflicts
and frustration that arise in attempting to combat prescription drug abuse from the
perspective of pharmacists.
Conclusion. Pharmacists view the drug as fragmenting the addict into two
individuals—a consumer composed of biological processes, what I call the ‘true patient’,
and ‘the addict’ characterized by psychological unawareness of these processes—and
doing so allows pharmacists to partially resolve their conflicts. While they more often
than not end up dispensing the medication even though they suspect abuse or diversion,
pharmacists can ameliorate some of the tension that arises. The subsequent chapter will
expound upon another way pharmacists ease the tension pharmaceutical drug abuse
creates by viewing the drug as overpowering the individual and challenging the authority
of doctors by blaming them for abuse. However, first, I will argue for the view that
pharmacists make a compromise in handling prescription drug abuse in the way described
here. Merriam-Webster defines compromise as, “settlement of differences by arbitration
or by consent reached by mutual concession; intermediate between or blending of
qualities of two different things; a concession to something derogatory or prejudicial.”
Hassling the patient allows the pharmacist to make their dissent known and they do not
view this as poor care, but rather “the poker face, the front of professionalism.”
Pharmacists are essentially able to make a compromise: they generate profit by
dispensing the script in service of their business ethos as well as the consumer, while
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hassling the addict to attempt to “make them answer me that they’re not using [the
medications or medical equipment] legitimately.” While defining addiction as the process
by which a drug fragments an individual and renders them unaware of their dependence
is the very source of their immediate conflict in dispensing drugs of abuse, the view
offers pharmacists a way to compromise between their business and care ethos. In the
next chapter, I will expound on how this view of abuse also offers the logic to more fully
ameliorate the ethical and role tensions prescription drug abuse arises. Thus, pharmacists’
view of drugs and addiction, as well as the effects of these on the human body creates the
problem they struggle with but ultimately offers a net positive solution to the highly
constrained nature of their paraprofession in handling prescription drug abuse.
In conclusion, I have introduced the nature of pharmacists’ daily work as they
attempt to navigate two different roles, an employee of a corporate (or for some
pharmacists, an independent) business and medical care provider. I have described how
prescription drug abuse brings pharmacists’ roles as drug expert and patient advocate into
conflict as pharmacists attempt to pursue profit while attending to patient care when the
medications are no longer seen to provide therapeutic value. I also explicated how
pharmacists’ decision making is predicated on the view that drugs have the capability to
fragment the individual into a ‘true patient’ composed of biological processes naturally
occurring in response to long-term maintenance on pharmaceuticals (dependence), and
‘the addict’ who is unaware of their dependence. In an analytic framework, pharmacists’
construction of the addict is rooted in the contradictions inherent in the problem and in
pharmacists’ competing interests in generating profit and attending to patient care. While
the addict’s unawareness is the very factor that problematizes prescription drug abuse for
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pharmacists, adopting this view justifies pharmacists’ attempts to themselves at creating
agency through hassling addicts and the continued pursuit of corporate-defined profitgenerating work.
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Chapter V: Pharmacists and prescribers: Care and pharmaceuticals amidst prescription
drug abuse
In the last chapter, I argued that pharmacists’ work is partially governed by sets of
business and care ethos. Their business ethos is comprised of the drive for profit imposed
by the corporate structure in which pharmacists relative to other medical practitioners are
employed. Additionally, this corporate structure also contributes to pharmacists’ status as
paraprofessionals making their work contingent upon the superior authority of doctors.
The hierarchical nature of their work and pharmacists’ place at the bottom of this
hierarchy makes their position highly constrained with low agency, autonomy, and
authority. Yet, pharmacists are still invested in the patient’s health and well-being, which
constitutes their care ethos. On the job, pharmacists similarly describe acting as drug
experts as well as patient advocates. These roles are sites where their business and care
ethos are co-existing, meaning these ethos are not discrete.
Prescription drug abuse brings these roles and ethos into conflict. Pharmacists
define addiction as dependence without awareness, creating a fragmentation between the
body and mind of the addict. Thus, in dispensing the medication without a “legitimate”
diagnosis, pharmacists do not view this behavior in line with their care ethos. Yet,
pharmacists must contend with more often than not having to dispense medications when
they suspect abuse. To handle this and reduce the role and ethical tensions pharmacists
feel, they fragment the individual into a ‘true patient’ and ‘the addict’. Hassling addicts
provides an avenue of agency, an attempt at bringing awareness of his or her addiction to
the addict in line with their care ethos, while pursuing their profit-generating work.
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Yet, the tension between these two roles exists largely with patients and
constitutes only one tension pharmacists contend with in the course of their day-to-day
work. Pharmacists’ labor is also inextricably tied to the role of prescribers. While
pharmacists overwhelmingly blame physicians for prescription drug abuse, in practice,
they perceive their role as monitoring doctor’s prescribing, seeing a managerial role for
themselves over prescribers. In order to play this role despite being paraprofessionals
with limited authority and autonomy, pharmacists disambiguate the medications they
dispense from the patients receiving those medications. By conceptualizing their work in
this way, pharmacists are able to establish a “turf” centered on medications and separate
from prescribers’ “turf” concerning patient care. Patient histories and records legitimize
to a certain extent their labor both to themselves and physicians. However, pharmacists’
orientation to medication catches them in the crosshairs of two competing dialogues: the
medicalization of addiction, which argues addiction is a disease, not a personal failing,
and pharmaceuticalization, which is the notion of medications as panaceas for numerous
states of ill health on one hand, and the language of care and patient interests.
Pharmacists strictly see the medications as their “turf”, but prescription drug abuse has
recast some medications as agents of harm, not agents of health. As a result, pharmacists
regard their interaction with prescription drug abuse ambivalently. As the medical system
has increasingly become predicated on pharmaceuticals, how professionals absorb these
new definitions in their daily work has profound implications for the state of prescription
drug abuse, the discipline of pharmacy and the self.
“You don’t have a problem with him forging your signature?”: Prescribers,
customers, and patients. Tom Wilson was a good friend of the father of a friend of mine
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and I met him for burgers one weekend afternoon. Tom’s energy and enthusiasm belied
his age suggested by his decades of experience in community pharmacy. “I can give you
an example of something that will just crack you up,” Tom told me.
“A patient who had never been to us before…came in to our pharmacy
with a prescription from an emergency room from a hospital down the
road from us, two blocks away. For Vicodin. Maybe 15 or 20 tablets, not a
whole lot.
“Now, it’s not signed by the doctor. The doctor forgot to sign it. So,
the pharmacist said, “I’m sorry, but we can’t fill this. You’ll have to go
down and get it signed,” which is probably the wrong thing to do. The best
thing would have been to call and verify and take it as a verbal order and
be done with it. You know, this guy [is] probably a drug abuser; a guy
coming in from the emergency room and he’s needing meds, you know.
That’s why I mean sometimes we can be oh so cautious that it’s wrong.
And in this case, I think it might have been but anyway, the story gets
funnier.
“So, he leaves, you know, kind of shakes his shoulders, shrugs his
shoulders, and leaves and then he comes back and it’s signed. Okay? This
pharmacist already didn’t trust this person, so she’s going to call the
hospital and make sure that he actually took it back there and got it signed.
So, she calls and wants to talk to the ER doctor. The ER doctor gets on the
phone. She asks him and he says, “No, I didn’t sign anything.” She goes,
“Really?” He goes, “Don’t worry. It doesn’t matter. He really does need
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the medication; just dispense it.” She says, “you don’t have a problem
with him forging your signature?” He goes, “That doesn’t really matter,
just go ahead and dispense it; it’s fine.” So then, she comes back and she
talks to the two of us and I go, “Look, just fill it. You got a verbal order;
just, you know, sign it off as a verbal [order]. Let’s not make an issue. It’s
not a big deal.” Again, so we are trying to avoid a confrontation with the
customer [emphasis added] to say, “So, we just called and you didn’t send
it back there,” even though that’s the information we’ve received. Anyway,
we dispense it. The patient [emphasis added] leaves. We pull up another
signed prescription from this doctor, it’s his signature!”
Sitting in the restaurant, I wish I could say I was more surprised, but I have heard similar
such stories for the weeks prior from other pharmacists. I respond, “So, the physician
really did…” and I do not even need to finish my sentence. Tom jumps in, exclaiming
with more exuberance and surprise than I can between bites of my hamburger, “sign it!”
Contained in this one story are several themes key to understanding the care
pharmacists deliver and what tensions are intertwined with both physicians and patients.
First, the physician in Tom’s story is portrayed as otherwise preoccupied. Tom
concurrently introduced the previous story as a humorous one, as well as an example of
“one of the reasons I get so irritated with physicians.” The tension Tom feels in this
situation with physicians is both explicit and nearly palpable. Secondary to the fact the
physician forgot he had signed the script, Tom is also frustrated by the physician’s
laissez-faire attitude about the patient ostensibly forging his signature. From the
perspective of Tom, the physician seems to think actually signing and filling the script is
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a mere hurdle to getting the patient the medication to feel better. The physician’s
definition of care seems decidedly patient-centered that by extension is interpreted by the
pharmacist as a sign of professional disrespect. Next and perhaps most obviously, parallel
to the tension Tom feels with the physician, is the tension between the pharmacist and the
patron. In sending the patient back to the hospital to get the script signed by the doctor in
lieu of calling to verify and taking a verbal order in the first place, the pharmacists are
challenging the patient’s trust. They will call the hospital and verify the prescription
regardless. Then, these actions by pharmacists are essentially moral. Thus, parallel to the
tension between pharmacists and physicians, is that between pharmacists and patients.
Third, Tom easily transitions into and out of referring to the patron as both a “customer”
and a “patient”. Before the financial transaction, he is a customer, but once money
exchanges hands, the customer becomes a patient. This fact bears on the final theme of
this story: pharmacists’ care is essentially drug- (not patient-) centered.
“Why is it our problem?”: Blame and ambivalence in the turf battles between
prescribers and pharmacists. From the outside as often appears to patients, the roles of
pharmacists and physicians appear intersecting and unidirectional; physicians write the
scripts pharmacists must fill. Pharmacy training deals extensively with the side effects
and interactions of the different classes of medications. As the number of
pharmaceuticals on the market has increased over the decades along with off-label use of
medications, this knowledge has become increasingly complex. However, this brings
pharmacists with knowledge of the medication, into conflict with physicians who have
knowledge of the patient and his or her diagnosis. Perhaps the most apposite example is
one provided by a student pharmacist in her internship. She detailed a battle she was
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currently undergoing with a physician about dosing with gabapentin. “[The attending
physician] wants more and more research because he doesn’t believe me…[Gabapentin]
is not doing anything above a certain dosage…it’s maybe not harmful to the patient; it’s
just what’s the point of giving them 1200 milligrams extra that they don’t need?...[the
pharmacist and I] have about five studies…we’re waiting to present it to [the prescribing
physician].” She and the other pharmacist repeatedly provided the prescriber with
research supporting their claim to no avail. As in this example, pharmacists’ knowledge
of pharmaceuticals is the one crucial area on which to challenge doctors’ authority,
particularly when doctors may be inclined to overprescribe medications.
As paraprofessionals, pharmacists often must mediate between patients and
prescribers. In such mediations, pharmacists feel tension both with the addict and with
the physician writing the script. Their futility is somewhat quelled towards patients due
both to the fact pharmacists see them as much as customers as patients, as well as how
they conceptualize addiction. However, pharmacists continue to feel tension with
physicians, who pharmacists place primary blame on for the emergence of prescription
drug abuse. Pharmacists are taught a language to engage with prescribers that reflects
how they would like to be seen by prescribers and teaches pharmacists to handle the
tension caused by their unequal authority. In the training program I observed, students
were taught to make suggestions to doctors without questioning their authority. Pharmacy
students were encouraged to say things such as, “I understand why you thought that way.
I was thinking this drug might be better for the patient because…”. On one hand, this
language reflects the real-life constraints of negotiating on the job, particularly with those
of higher authority; however, this advice also teaches students how to wield their limited
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authority and practice within the constraints set by their status as paraprofessionals.
Avoidance of words such as “but”, which change the tone of the sentence and referencing
what “might be better for the patient” reinforce the common goal of patient health
without referencing the power differential that exists between physicians and pharmacists.
The language training programs encourage their students to employ with doctors
echoes the “spin selling” Oldani (2004: 328) describes between drug representatives and
physicians. “Every objection (by physicians, patients, and the general public) can be
turned around to become a positive selling point, something to be valued and sold for the
patient’s benefit” [emphasis in original]. Oldani describes how the doctor’s initial
objection may have been a “language game” to see if he, as a drug representative, would
“be nasty towards the competition, usually not a good idea (the doctor and the
competition may be golfing partners)” (2004: 328). Pharmacists were taught to elicit
objections from prescribers and explain how another treatment regimen may better serve
these ends without necessarily contradicting the doctor. Whether the adoption of this
technique from the pharmaceutical industry was intentional or not on the part of faculty
in a pharmacy training program is tertiary to the manner in which pharmaceuticals and
their effects are actively shaped through language and social exchanges always couching
these effects as in the patient’s, not the pharmacists’, industry’s or prescribers’, best
interest.
Often belied by the non-accusatory language they are taught in school and when
not engaging with prescribers, the pharmacists I spoke with unilaterally placed primary
blame on physicians for the acceleration of prescription drug abuse. While their
admonishments of society or patients were often vague and ill defined, pharmacists were
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verbose with their blame of prescribers they see as abusing their authority. Tom, the
pharmacist in an independent, community pharmacy for decades, wondered, “what’s
going on in that office visit? What’s that person telling you [the doctor] and what are you
believing? Sometimes, I think, ‘How naïve can you be, Doctor so-and-so? How can you
think this is legitimate?’” Along these same lines, one pharmacist comically described
what he calls “get-the-hell-out-of-my-office scripts, where they’ll write like five
Hydrocodone just to get ‘em out. It’s like, ‘Oh, well it can’t hurt them because it’s not
enough Tylenol for a daily dose. So, here’s five Vicodin. Go find another doctor.’ You
see a lot of that.” Another pharmacist referred to scripts for small amounts of Vicodin as
“calling-your-bluff scripts. ‘I don’t really believe that story you [the patient] are telling
me but I’m just going to give you a couple to appease you.” Pharmacists perceive such
scripts for small amounts of abusable medications as irresponsible on the part of
physicians and an affront to their professional duty.
Specifically, pharmacists regard such behavior on the part of prescribers to be an
offense because they perceive such script-writing as an attempt by physicians to place the
onus of responsibility on pharmacists for filtering out such patients who may be
attempting to game the system. Because five Vicodin is not enough to be considered
problematic prescribing and pharmacists have access to a kind of pan-record of patients’
medication history, pharmacists believed physicians to be pushing responsibility and thus,
liability onto pharmacists for dispensing to a patient who may have a record of multiple
fills of abusable medications. Whether prescribers have this intent is tertiary to the fact
pharmacists conceptualize their role in healthcare as monitoring both prescribers and
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patients. One pharmacist phrased this responsibility of managing physician’s prescribing
as “making sure that every doctor is prescribing within their practice limits”.
While pharmacists bemoan this responsibility, their language implies a perceived
“managerial” role above physicians. This claim is emboldened by what one pharmacist,
Ben, described as the culture surrounding abusable prescriptions as one of apathy on the
part of doctors. “Who carries the burden of responsibility?” I asked him. Without a
moment’s hesitation, he retorted, “Doctors. No doubt, it’s the doctors…I definitely put a
lot of the blame on doctors.” While he conceded that doctors frequently lack the time to
spend with patients, he thought doctors lacked “people skills” to give patients “insight”
into their prescribing and recommendations “as opposed to when I tell a patient to do
something, I say, ‘this is why I want you to take this. This is why I want you to do this. It
may seem unorthodox, but this is why I’m telling you to do this.’” Ben simultaneously
and explicitly notes the blame pharmacists place on doctors for prescription drug abuse,
as well as the closeness he feels he has with his patients. However, it is the
paraprofessional role of pharmacists that allows such “closeness”. Implied by such
statements is the fact that the proliferation of prescription drug abuse problematizes the
professional relationship between pharmacists and prescribers. Pharmacists couch the
problem as an opportunity to have oversight over doctors, reorganizing the typical
division of labor. While physicians would refute this perception, the trick of perception
has limited functional utility, but is a psychological tool by which pharmacists cope with
having low professional autonomy and authority.
While pharmacists profess they have a duty as part of their profession to monitor
physician’s prescribing, they do not perceive this duty as allowing them to shoulder any
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blame for the problem. Instead, they are quite critical of prescribers. Their blame serves
two ends. Blaming physicians aids pharmacists’ moralization of patients. By constructing
a dichotomy through blame—pharmacists versus physicians—pharmacists are able to
imply their work is more moral and in better service to the “true patient,” even if
physicians do not recognize, as pharmacists accuse, that they are actually prescribing to
addicts. Physician blame also serves to set the boundaries of their profession. Such
accusations bolster pharmacists’ perception of a lack of education among physicians on
medications. One pharmacist told me “doctors are really good at diagnosing, that’s what
they are really good at, working with the patient one-on-one to figure out what the
problem is,” carefully talking around a perceived lack of knowledge pharmacists believe
doctors have concerning medications. Another pharmacist went more in depth about the
different “turfs” doctors and pharmacists occupy,
“I don’t…no, I don’t think, doctors have adequate training on medications.
I think though what you’ll find is if you took the average, say internal
medicine doctor. Internist, okay? And ask them routinely, how many meds
do they prescribe? I bet it’s less than 50. I mean, there’s 10,000 drugs on
the market; they don’t prescribe 10,000 different products. Mostly, they’ll
have a very small group of medications that they prescribe. And you know,
I could probably name most of them right now, the anti-hypertensives,
drugs for cholesterol, drugs for diabetes… But most
doctors…don’t…prescribe outside of their comfort zone. So they do keep
it close to the vest, I think. Cuz they…you know, they’re trying to do a

	
  

	
   63	
  
good job, too. You know? So they don’t want to start prescribing stuff that
they’re not too familiar with.”
As this pharmacist alludes to, pharmacists consider medications their domain and resent
physicians they feel misprescribe certain classes of drugs. In blaming physicians for
prescription drug abuse, pharmacists effectively disambiguate the medications from the
patient. Pharmacists effectively maintain their claim to medications being in their domain,
but leave responsibility for both the ‘true patient’ and the addict within the bounds of
prescriber’s professional realm.
Yet, pharmacists alternately express reluctance at taking on a larger role in
combating prescription drug abuse while bemoaning their lack of professional authority
and autonomy to enact their will. Due to this, pharmacists conceptualize a key role for
themselves in healthcare as monitoring patient’s consumption and use of medications.
Part of enacting this role is monitoring doctor’s prescribing. Pharmacists exist, in one’s
own words, to get “the right drug to the right patient at the right time.” Pharmacists must
be capable of challenging doctors or patients when either contradicts this dictum. Yet,
pharmacists must rely on doctors to write prescriptions and patients to patronize their
business. One of the few avenues pharmacists have to autonomy on the job is deciding
whom to appease and whom to antagonize. Their ambivalence allows them to alternately
criticize and rely on physicians and patients as necessary. Ambivalence, along with
blaming prescribers, then becomes a tool, unique to paraprofessionals, for pharmacists to
create professional distance from patients or prescribers who may attempt to challenge
their limited authority. The distance created through ambivalence and blame allows
pharmacists to carve out their “turf” in the professional landscape. They see physicians’
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realm as patient treatment outcomes and their “turf” as monitoring the flow and
consumption of pharmaceuticals. By regarding both prescribers and patients ambivalently,
as well as blaming prescribers, pharmacists attempt to set the bounds of their profession,
legitimizing their position in the medical hierarchy, and constructing their own values
system.
Pharmacists adopt a similarly ambivalent attitude towards prescription drug abuse
and diversion. Every pharmacist I spoke with had at least one instance where they
recounted an abuser they reported to a prescriber. Pharmacists recount these stories with a
sense of pride and at times, their body language while retelling these stories would hint at
feelings of superiority over doctors in their ability to detect these instances of abuse. First,
pharmacists have the ability to work with insurance companies to see if a patient has
received the same medication in the recent past. As I described earlier, pharmacists feel
physicians rely on them to thwart patients who “doctor shop” for their medication,
referring to the practice of visiting several prescribers seeking multiple prescriptions for
the same medication. Of course, this strategy is limited to patients with insurance. For
those without insurance or state aid, pharmacists still have exclusive access to all patient
histories, a kind of pan-medical record of patient’s prescriptions. However, more often
than not, pharmacists end up dispensing abusable medications and in this case, patient
histories are the only record they have of their suspicions. Pharmacists I spoke with were
adamant in their support for prescription drug monitoring programs, which would
increase the control they have over whether to dispense medications or not by providing
them with a complete record of each individual’s prescriptions, making it easier to catch
“doctor shopping” and similar behaviors that flag abuse. Such monitoring programs
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increase pharmacists’ professional autonomy and control over their product, key factors
in the development towards full professionalization.
While pharmacists enthusiastically supported prescription drug monitoring
programs and expressed desire to achieve greater autonomy and control on the job, they
quickly backtracked when discussing such drug monitoring programs in the context of
prescription drug abuse. Overall, pharmacists’ attitude towards intervening in
prescription drug abuse could be described as ambivalent as well: they prized moments
when they were able to challenge doctors’ authority and call the prescriber’s attention to
a patient who was “doctor shopping” and welcomed the emergence of prescription drug
monitoring programs, but were steadfastly resistant against taking on any role to formally
intervene in the problem, saying it is the fault of doctors and doctors must resolve the
problem. Their ambivalence allows pharmacists to challenge doctors by assigning them
blame for prescription drug abuse in seeing it as a ‘patient problem’ (not a ‘drugproblem’), but maintain their perceived role as monitoring both patient consumption and
physician prescribing. Together, these views, although seemingly contradictory, allow
pharmacists to insulate themselves from accepting the blame for prescription drug abuse.
One of pharmacists’ most fundamental doctrines is that addiction is created by a patient’s
use, not the chemical properties of a pharmaceutical. In seeing doctor’s “turf” as patients
and addiction the result of bad patients, pharmacists are able to maintain the sovereignty
of doctors over their patients, insulating themselves and the pharmaceuticals from being
viewed as the agents of addiction.
Pharmacy records in legitimating work and in coping with frustration.
Pharmacists currently have access to records within their chain of every person who has
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filled a script at any location in the country. Pharmacists can also add subtle notes if they
suspect a patient is abusing. One pharmacist described including these notes: “We try to
keep comments on profiles. We have to be really professional about this. We can’t say
something like ‘This patient will scream and yell if you don’t let their medication go
early.’ You can’t write stuff like that. What we have to say is like ‘Watch for early refills.
Watch Lorazepam [Ativan, a commonly abused anxiolytic] use.’ Stuff like that. That’s
how we have to try to go about that.” Thus, such records contain not only a history of the
patient’s business transactions, but also of communication with patients and whether the
patient is suspected of abusing or diverting their prescriptions.
The role of pharmacists’ records and the kind of record prescription drug
monitoring programs offer should not be understated for its role in legitimizing
pharmacists’ knowledge and work. While their ambivalence legitimates their position in
relation to physicians and patients, their records play an important role in legitimating
their work, particularly when they suspect abuse but are unable to keep from dispensing
the medications. Many times, pharmacists told me instances where they had to dispense
potentially illegitimate prescriptions, “you document the heck out of it. Just document the
snot out of it in case somebody comes back, in case there is a lawsuit, in case there is an
audit.” First, such records provide a perceived unbiased perspective on which to
challenge doctors and physicians when their professional position alone does not warrant
such antagonism. Second, patient’s history also legitimizes pharmacists’ work by
providing a record of their labor and patient interactions. Pharmacists come into contact
with patients only briefly and are usually left unaware of patient health outcomes. Patient
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records provide an inventory of their labor and a tangible artifact of their efforts at
recognizing abusers.
In the milieu of Brodwin’s description of an “assemblage of compliance”, such
records compose an “assemblage of awareness” (2010: 130-1). The definition of
assemblage he provides is astute, “a whole constructed of heterogeneous parts that retain
their distinctive identity…the notion of social assemblage insists that the various
components do not really aggregate; they come together contingently at particular
cultural and historical periods.” (2010: 130). The patient records unique to a particular
pharmacy chain and Prescription Drug Monitoring Programs (PDMPs), which at their
most fundamental function collect these records from all pharmacy chains, are constituted
by disparate components from different pharmacists and different settings detailing all
aspects of pharmacists’ exchange with patients. The medication(s) a patient receives,
recommendations and instructions for their use (i.e., “take this food”) and suspicions (i.e.,
“watch Lorazepam use”), as well as if contact with police and law enforcement are made
can all be combined in this one data source. For such problem cases, pharmacists’ hope is
that this will facilitate prosecution should a patient demonstrate an ongoing pattern of
behavior consistent with drug-seeking or at least absolve them of legal, if not ethical,
responsibility for dispensing in such situations. The ultimate goal of these is for them to
accumulate a tangible show of problematic behavior to encourage the patient to become
aware of their irresponsible use perhaps in the pharmacy or in the courthouse. Since
awareness is the key factor delineating problematic addiction from mundane dependence,
this assemblage of awareness is the last vague hope pharmacists have of combating
prescription drug abuse.
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After all, even when pharmacists are able to positively identify an abuser and call
the police, pharmacists make a costly time investment, which they see contradictory to
both their care- and business-centered ethos. One pharmacists told me a story where he
dispensed Ativan to a patient he suspected of abusing, just to have another customer
come into the store and tell him he was trading the medication for cash in the parking lot.
“You go to all this work, you waste an hour like calling the police
department “Alright, I need a case number.” You call the doctor and say
“Hey, I have this case number where this patient’s medications were
stolen and his son came into his house and beat him up is what the guy
said.” And then you get doctor’s approval to let it go, state approval to let
it go, police work…it takes a lot of time! And that holds you back from
being able to help other people too. And, just to hear that it went out
means…I mean, someone described the hat he was wearing, clothes and
everything and yeah, he was just talking to another guy, handed him a bag,
and took a bunch of cash and…that was frustrating.”
Despite pharmacists’ best intentions, they often have only a note in a patient’s profile of
their time spent following up on the problem. As the quote implies, the work is
frustrating both in its fruitlessness, as well as the fact it fails to serve either care- or
business-centered goals. In documenting not just a financial transaction, but a record of
what was dispensed or discussed, and sometimes their suspicions of a patient’s abuse in
muted terms, pharmacists are at least able to align themselves with traditional careoriented goals through these records enabling them to make appeals to doctors in the
name of the patient’s interest to not dispense in cases where they believe a patient should
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not receive medication. Additionally, such records are often the only outlet for
pharmacists to express their frustration albeit in restrained terms at dispensing to those
they believe have illegitimate intentions, helping to legitimize their work to themselves.
Prescription drug abuse: Shifting the definition of care. In summary, pharmacists’
blame of prescribers for prescription drug abuse creates a schism between pharmacists
with knowledge of pharmaceuticals, and prescribers trained in patient care. Pharmacists
are able to establish a “turf” for themselves as managers and monitors of physician’s
prescribing and patient’s consumption of medications. In adopting the dictum that there
are no bad medicines, only bad patients, pharmacists are able to separate blame and
responsibility for the problem from the medications and their challenges to doctors’
authority. Adopting this ambivalence legitimizes their status as paraprofessionals, largely
dependent upon the work of prescribers and seeking greater autonomy and authority, but
not taking on blame or responsibility for a problem they define as a problem with patients
and thus a doctor’s concern. Patient histories and the notes pharmacists include provide a
material link at their effort to boost their attempts at adopting more authority and
autonomy through identifying abusers and stopping the flow of medications to these
individuals; attempts that frequently prove futile to the great chagrin of pharmacists. Such
records are an invaluable tool for pharmacists to legitimize their efforts, at least to
themselves. Instead of making attempts to increase their professionalization per se
through combating prescription drug abuse, pharmacists seem to be challenging the
supremacy of prescribers and physician’s definition of care in prescribing to addicts.
Amidst their attempts at combating prescription drug abuse, pharmacists must
maintain healthy working relationships with doctors of higher authority because doctors
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provide pharmacists with a potential powerful ally against a problematic patient. I have
already described how pharmacists often have the knowledge of a patient’s history used
to identify “doctor shopping” and potential abusers to physicians. Yet, it is the relatively
rare occasion when pharmacists are able to use this knowledge without referring to the
authority of a physician or insurance company to deny dispensing medications. However,
mostly, pharmacists dispense medications in such situations, feeding their alternating
reliance and frustration towards prescribers, or their ambivalence. One pharmacist
expressed the anger that results from such futility in saying “pharmacists get real
frustrated like, why is it our problem? You know, why do we have to be the police?”
While, it is certainly true this work falls to pharmacists as paraprofessionals to do the
“dirty work”, the futility pharmacists frequently experience on the job and their
ambivalence towards prescribers suggests a fundamental disconnect worth exploring
between pharmacists and prescribers: a disconnect between pharmaceuticals and patient
care.
While pharmacists steadfastly see medications as benevolent and instead cast
individual’s use of medications as harmful, prescription drug abuse has nevertheless
redefined medicines as not only agents of health, but also as agents of harm. In this way,
pharmacists’ work in dispensing such medications is often antithetical to patient care and
treatment outcomes, aspects largely defining doctors’ work. Then, pharmacists are
brought into professional conflict with physicians and medications are brought into
conflict with patient care. The tension between pharmacists and prescribers mirrors this
tension emerging between medications and patient health.
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For the purposes of this work, care is defined as an iterative, individualized,
holistic and actionable (versus moral) process, which involves the patient as active
subjects (Mol 2008). This idealized version of care can be contrasted with a “second
logic of care” emphasizing patient choice and which views patients as consumers. While
one logic of care involves the patient in defining the standard, “what follows is that for
the logic of care gathering knowledge is not a matter of providing better maps of reality,
but of crafting more bearable ways of living with, or in reality” (Mol 2008:46). The
transaction of pharmaceuticals in exchange for a doctor’s script and money is inherently
economic in nature and lends itself to the second logic of care Mol details. Yet, when the
very product meant to deliver care in shifting contexts becomes an agent of harm, these
two logics intertwine and often, strictly contradict each other and new facets to the
definition of care emerge.
Unlike prescribers, pharmacists deal much more extensively with medications,
especially with patients’ use of medications via side effects or contraindications.
Pharmacists appreciate opportunities to educate patients on medications and feel they
have a role regarding patient care as patient advocates. The way one pharmacist I spoke
to described her role in the medical hierarchy reflected the potential for conflict in
enacting this role with patients. “I’d say we’re patient advocates…protecting a patient
from themselves sometimes whether they like it or not.” Implied in these words is the
necessity of antagonizing patients. “We have the information to help people to try and
take medication properly. Taking medication improperly can be as harmful as it can be
beneficial,” one pharmacist extolled his skills. As these quotes suggest, pharmacists view
pharmaceuticals as inherently health-promoting; an individual’s use of the medication
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determines whether the substance is harmful or healthful. Put another way, there are no
bad medicines, only bad patients.
In the same way pharmacists have adopted this dictum, the dialogue of
prescription drug abuse has adopted an insular attitude towards the products of major
pharmaceutical corporations. The medicalization of addiction created the notion of
addiction as a disease, instead of the result of personal moral failings. Pharmacists
absorbed this thinking in conceptualizing the ‘true patient’ as opposed to the addict.
However, as the breadth of pharmaceuticals came to include ones capable of producing
potent, addictive effects, pharmacists along with the rest of the medical community as
well as society as a whole, continue to contend with the medications we have come to
rely on being powerful agents of harm. Pharmacists grapple with the changing context of
pharmaceuticals from curative agents to agents of harm in their daily work. On one hand,
medications are viewed by pharmacists as inherently benevolent, addicts as victims of a
disease, but a disease caused by medications they are believe to be wholly healthpromoting. Thus, pharmacists’ ambivalence is the result of a wider ambivalence
emerging around prescription drugs. To gain increasing control over the product and
achieve more professional autonomy would accompany accepting responsibility for a
tension yet to be resolved.
As in the story to introduce this chapter, pharmacists represent a medicationcentered approach to care brought into conflict with physician’s patient care-centered
paradigm. Similar to how Tom conveyed tension with the patient, pharmacists are unsure
to a certain extent how to incorporate the prescription drug addict into their daily practice
and thinking. While pharmacists desire more professional authority and autonomy, they
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are constrained in how to combat the problem. They use language unique to their position
as paraprofessionals to either couch their work as business by referring to individuals as
“customers”, but once money has exchanged hands, they easily refer to the customer as a
“patient”, switching their script. Since the only recourse of action they have to combat
prescription drug abuse centers around how to keep medications out of the hands of
suspicious patrons, once they dispense the medication, pharmacists are able to see the
individual as a patient. Since pharmacists’ care is medication-centered, they have the
opportunity to provide their version of care only after the medication has been dispensed.
Tom’s story of the patient filling a script for Vicodin contains the tension he feels with
prescribers, as well as patients/customers, and how they conceptualize care. Pharmacists’
ambiguity regarding prescription drug abuse reflects a deeper and wider tension existing
between their conceptualizations of medication and care.
Conclusion. In instances of abuse, the patient becomes a site wherein pharmacists’
care and business ethos are brought into conflict. Despite the low professional authority
or autonomy of pharmacists, they find ways to gain agency to enact their own moral code
and in so doing, help ameliorate the tension between their two roles. Pharmacists can
choose to detach from patient care by removing the label of “patient” entirely and
categorizing patrons as addicts or portraying them merely as consumers or customers.
Doctor blaming challenges the position of doctors and allows pharmacists to assert their
authority, at least to themselves, in the face of the futility caused by having to dispense
abusable medications to addicts—an act pharmacists see as contradictory to care.
Physicians are regarded both by pharmacists and in the professional literature as full
professionals, whose efforts are directed at patients towards offering care in the form of
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better health. Pharmacists’ position as paraprofessionals equally situated at the interstice
between care and profit must redefine the meaning of care. How pharmacists define care
in light of these competing ethics has implications for how they conceptualize and handle
prescription drug abuse. In other words, pharmaceutical drug abuse requires pharmacists
to re-imagine their definition of care.
Pharmacists’ view of their work, and the ethics that guide it, allow them to
antagonize patients and refuse to dispense and cast it as care, particularly when taken in
light of their definition of addiction as splintering the mind from the body of the addict.
Pharmacists often dispense medications when they do not believe they should. Patient
histories legitimize this labor and allow them tangible proof to fight physicians’
prescribing and combat the futility of operating with low professional autonomy.
Pharmacists are rarely aware of patient treatment outcomes, although they feel invested
in the impact of medications on patients’ health, so pharmacists create a distance between
their role in healthcare and the patient, disease, and treatment outcomes. Care is redefined as knowledge of pharmaceuticals and the laws that govern the dispensing of these
drugs.
In summary, pharmacists feel great tension with prescribers. By disambiguating
the medications they dispense from patients, pharmacists can legitimize their blame of
physicians by moralizing patients and viewing drugs as inherently health-promoting.
Patient histories and records provide justification for challenging physicians on scripts
and play a key role in allowing pharmacists to blame physicians, connecting physicians to
patient care, and providing pharmacists an outlet to express their true suspicions when
they dispense to people they suspect are abusing or diverting their prescriptions.
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Pharmacists’ care is medication-centered, but prescription drug abuse has recast
medications as potential agents of harm. While medications have been heralded in
modern medicine as the panacea for any array of health problems, trends of
medicalization have promoted the view of addiction as a disease, not a personal moral
failing as it was historically viewed. The ambiguity pharmacists have towards their work
and the tension pharmacists as medication-centered paraprofessionals feel with
physicians, as professionals in charge of patient care, reflect the tension existing between
these two competing dialogues: pharmaceuticalization and prescription drug abuse,
medicines and patient care.
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Chapter VI: Conclusion
The presence of competing dialogues—between medicalization and prescription
drug abuse, medicines and patient care—is replicated in other contexts. The University of
Wisconsin Pain & Policy Studies Group continues research advocating for increased
accessibility to prescription narcotics for non-terminal patients. While the group publicly
announced in April 2011 they would no longer accept payouts from pharmaceutical
companies (Fauber 2011b), life goes on for David Joranson and Aaron Gilson, still
prominently employed by the group according to its website. Daniel Lee, the drug dealer
who robbed several area pharmacies in the backyard of the UW Pain & Policy Studies
Group, is still serving his sentence and will not be set for release until 2078, meaning Lee
will have to survive to the unlikely age of 115 in order to live free again (USDOJ 2013).
Yet, larger questions about the conflicts between patient care and the potential for
prescription narcotics to produce addiction linger.
For pharmacists, these tensions become ingrained in their day-to-day work. In our
discussions, discerning legitimate scripts from illegitimate scripts is a regular process and
these categories have no clear-cut boundaries. Instead, levels of legitimacy exist
depending on the patient/customer and the script itself. Pharmacists must strategically
infer these clues from a set of everyday knowledge garnered through years of formal and
informal training to make such decisions and in order to hypothesize the fate of the
medications once they leave the pharmacy and enter the community. Based upon the
regard for pharmaceuticals gleaned from both their formal academic training and societywide beliefs, pharmacists regard their job in producing a bottle of pills for a script and
money more than merely “pill counting” but a moral act. When all medications are good,
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pharmacists see it as their fundamental duty to keep the good medicines out of bad hands.
Yet, their actions so often fail their objectives.
It may seem easy to simply cast the actions of pharmacists as unique and their
inability to keep prescriptions out of the hands of abusers simply a professional failure.
However, increasing trends of prescription drug abuse demand a more thorough analysis.
Perhaps in some part either large or small, this trend is fueled by direct to consumer
marketing creating substantial demand for prescriptions among the public. From this
perspective, the medical system, not only pharmacists, is constrained by
pharmaceuticalization. Phamaceuticalization refers to “the process by which social,
behavioral, or bodily conditions are treated, or deemed to be in need of
treatment/intervention with pharmaceuticals by doctors, patients, or both” (Abraham
2010: 290). Patients expect prescriptions because medicines are equated with care and the
absence of pain or inconvenience. Doctors who prescribe, as well as pharmacists who
dispense these medications are continually caught between good intentions rooted in
patient care on one hand and economic and customer demands on the other.
Pharmaceuticalization has made prescriptions, of which increasing numbers are patented
each year, a social sign of care and concern. When medicalization produces diagnoses for
any kind of pain or discomfort, the dispensing of pharmaceuticals becomes a primary tool
to express care more generally.
The idea of pharmaceuticals as agents of care and concern that emerge from
trends of medicalization and pharmaceuticalization is supported by epidemiological
trends showing the vast majority of prescriptions individuals abuse are acquired through
friends or family members who share their prescriptions. Pharmaceuticals as currency for
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care extends beyond those with formal medical training, but are pervasive as a more
general societal value.
Review of my argument. Pharmacy, drugs of abuse, and addiction share a long,
intertwining history. Drugs such as heroin and cocaine were once medicinals used
legitimately among the well to do to treat several illnesses. As these substances became
associated with the world of leisure and particularly minority and immigrant populations,
increasing legal penalties prohibiting their use reinforced the existing social order (Acker
2002:2-9). Addiction emerged as a medical diagnosis in the early 1900’s amidst these
increasing drug penalties. Such laws did little to slow the productivity of new drug
development. A variety of drugs and methods to produce them in large scale developed in
the first half of the 1900’s. Certain drugs, such as the birth control pill, heralded eras of
social change like women’s liberation (Gordon 2002). In this case, the ability of a woman
to control her fertility by a self-administered and discreet pill essentially constituted an
act of social revolution. By 1959, over half a million American women were receiving
the pill for contraceptive purposes producing large profits for G.D. Searle and Company.
The notion that drugs could be symbols of social power was well embedded in the
American psyche, and debates concerning birth control continue today. By the 1970’s,
the Controlled Substances Act was passed that attempted to establish set prescribing
patterns. In allowing certain drugs to be automatically refilled without needing a doctor to
write a new script and in combination with the deinstitutionalization movement heralded
a new pharmaceutical era (Szasz 2007). Demand for these drugs fueled drug development
by pharmaceutical companies. The emergence of Prozac in 1977 for the treatment of
depression ushered record profits for the pharmaceutical industry and other companies
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worked on developing their own version of Eli Lilly and Company’s discovery (Healy
2006). Among these discoveries was hydrocodone that, when combined with
acetaminophen, not only proved to be an effective analgesic, but a less tightly regulated
Schedule III drug, bringing billions to Knoll Pharmaceuticals. While the drug was
originally developed for use in terminal cases, in 1985, opinions began to emerge that
such drugs had a therapeutic utilization among non-terminal patients. One such article
described “opiophobia” among physicians that causes them to underprescribe opiates, or
narcotic analgesics. “As a result of this practice, many patients undergo needless pain and
suffering. Equally important, failure to use these drugs appropriately undermines the
physician-patient relationship” (Stimmel, 1985). These words explicitly state the
professional duty of those in medicine is to absolve pain and the value of drugs such as
Vicodin to enhance the relationship between patients and their doctors. Ostensibly, the
underutilization of opiates was tied to the illicit nature of related drugs such as heroin,
heavily racialized and stigmatized dating back to its emergence among minorities and
immigrants in the late 1800’s. Like psychiatric diagnoses, pain is a state of suffering not
readily translated to the atomized and materialistic terms of biomedicine. Pain can be a
global complaint, not limited to one body part, and no swab or culture can prove its
existence. A diagnosis of pain is based entirely on patient self-report and a doctor’s
recognition of this complaint and counteraction of writing a script for Vicodin to
ameliorate this pain constitutes an act of care for which no other alternatives may exist.
Drugs and particularly opioids are not value-neutral; instead, their prescribing, dispensing,
and consumption constitute a social and moral act.
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Pharmacists see these dramas play out in their daily work, as documented herein.
They operate within constraints set by their paraprofessional role, as well as the demand
for profit and general desire to provide care and ameliorate illness. However, when
required to dispense drugs of abuse to those they suspect are abusing, the social and
moral power they view drugs as having becomes ever more salient. While all patients
habituated on a drug will develop dependence, tolerance, and withdrawal, they claim,
addicts are in denial about these effects of the drug on their body. As part of this dialogue,
the conceptualization of drugs as agents of health and prosperity remain intact; addiction
is a disease of the brain, more specifically of a brain-body disconnect. Pharmacists are
purveyors of the universal good: medications; however, they see prescribers as laying
professional claim to patients. Then, pharmacists as not-full-professionals are able to
fully lay the blame for prescription drug abuse at the feet of physicians. Pharmacists are
able to attempt to pursue their care-oriented goals by hassling those individuals they see
as not worthy or deserving of the medications. Meanwhile, they produce an assemblage
of patient records, often compiled into a Prescription Drug Monitoring Program
(PDMP)—a tangible record of their negotiations between the often-competing interests of
doctor, patient, and pharmacist. Providing this semi-public show of their work and
suspicions of abuse is useful in the face of the futility of attempting to fight the
proliferation of pharmaceutical agents.
Although they place heavy blame on physicians for prescription drug abuse,
pharmacists also must rely on physicians to predicate their work. Ambivalence emerges
allowing pharmacists to effectively carve out their professional turf in the face of low
authority or autonomy to formally do so. A decidedly medication-centered approach to

	
  

	
   81	
  
care emerges. Not only are medications the primary object of pharmacists’ work, but they
provide the means of profit and their therapeutic effects satisfy pharmacists’ wellintentioned goals towards patient care—a key difference between full professionalization
according to Freidson (1974:71-84). However, when dispensing to addicts, perceived as
bad patients who lack awareness of the powerful effects of drugs, pharmacists face
competing dialogues: medications they are heavily invested in as therapeutic agents
become agents of disease. Yet, the receipt of these drugs constitutes a powerful and
pervasive definition of care bolstered by a history of drug-driven social change and gross
expansion of the market for pharmaceuticals.
Pharmacy becomes a key site for these dialogues to occur. Pharmacists’ labor is
more explicitly business-oriented; as paraprofessionals often physically located in
business sectors outside of hospitals or clinics, they are without many of the trappings of
physicians and their professional codes of patient care as a higher order value, and
pharmacists are explicit in their pursuit of profit in the name of healthcare. Their training
and labor is centered upon the drugs themselves, not their effect on patient outcomes.
Pharmacists essentially exist betwixt-and-between business and healthcare and the fully
professional world of prescribers and the community of patients and customers.
While the constraints pharmacists operate within are readily identifiable as part of
their paraprofessional role, they are not unlike the constraints imposed on society at large
from which an increasing demand for such drugs exists. If the pharmaceutical market is a
zero sum game between medical professionals attempting to keep abusable prescriptions
within a legitimate sphere and patients intent on using these drugs for illicit purposes, the
estimated 7 million persons abusing prescriptions drugs annually are simply no match for
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prescribers and pharmacists. Yet, the line demarcating licit from illicit use of such
substances proves to be an incredibly thin one. Pharmacists described tolerance and
withdrawal as properties of any drug a patient may become habituated on. They described
the effects of suddenly discontinuing any medicinal regimen from blood pressure
medication to antidepressants. Their claims are bolstered by professional organizations of
prescribers, such as the American Academy of Pain Medicine. In a press release from
2003, they state “long term use of opioids results in physical dependence, which is
different from addiction, but does not usually lead to addiction. Physical dependence
[emphasis in original] is a normal adaptive state, the expected result of using pain
medicine (as well as other medications) for a long time.” They define addiction as
“characterized by impaired control over drug use, compulsive use, and continued use
despite harm and decreased quality of life” echoing the DSM (2013) definition of
substance dependence, i.e., a lack of awareness of the drug’s ability to direct behavior
and influence the body.
While chronic abuse of illicit drugs are couched in terms such as tolerance and
withdrawal outlined by the DSM, a special term exists to describe the effects a person
will experience with suddenly stopping use of their antidepressants, discontinuation
syndrome. This term emerged following a symposium hosted in 1996 by Eli Lilly and
Company, the makers of Prozac, as well as an array of other psychiatric medications
(McHenry 2006). The symposium was held in response to growing criticism that some
patients experience difficulty in getting off their antidepressants. Eli Lilly had estimated
“at most a few percent” of individuals would experience the onset of symptoms following
discontinuation of antidepressants. However, research from Massachusetts General
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Hospital found this initial estimate to be far too low. Researchers found as many as
seventy-eight percent of individuals medicated on antidepressants will experience
symptoms following their discontinuation of the drug (Fava et al. 1997). While some
antidepressants are more prone to withdrawal symptoms than others (Zoloft and Paxil are
cited as particularly problematic in this regard; Zajecka, Tracy, Mitchell 1997), these
rates are significantly higher than the estimates provided by Eli Lilly. Following this
symposium, however, Eli Lilly established the term “discontinuation syndrome” in an
effort to distance their drugs from the terminology associated with abuse. Officially, such
drugs are not classified as having an abuse potential based on animal studies showing rats
provided free access to the drug do not seek it out. Yet, the commercials filling print and
video ads urging the public to “ask your doctor about [a drug] to see if it’s right for you”
along with increasing use of psychiatric and abusable medications attest to the fact that
individuals do indeed seek these prescriptions out under the urging of pharmaceutical
companies.
Conclusion. As these tensions make clear, the insistence of pharmaceuticals as
agents of health and well-being and only a patient’s use and perception of the drug’s
effects separate abuse from dependence more generally, are not perspectives unique to
pharmacists. Rather, it is a carefully and intentionally constructed dialogue of the
pharmaceutical industry that couches its products—be they ones more readily associated
with abuse, such as Vicodin or OxyContin, or psychiatric medications, but not excluding
other classes of medications—as the definition of care and a healthy relationship between
patients and the medical establishment, physicians, and pharmacists. Pharmacists actively
shape these dialogues as they educate patients about medication use and hassle patients
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they suspect abuse their drugs. As part of this work, they create an assemblage of
awareness; patient records, a tangible account of their reactions to patients/customers, an
assemblage of profit, care, biomedicine, a global pharmaceutical market, and the morality
that emerges to dictate how these disparate pieces coincide.
As a long history illustrates, boundaries ostensibly separating licit from illicit
drugs, from pharmacy, sociocultural change, and the pharmaceutical industry are shifting
and these components are continually being actively shaped to fit changing circumstances.
Similarly, the global, local, interpersonal, and internal factors all contribute to how drugs
and their use are conceptualized both in and out of the clinic or pharmacy. The body of
the addict, as the ideal patient and consumer, becomes an active site for these discourses
to play out as the persuasive techniques adopted by the pharmaceutical industry and
medical professionals both attempt to bridge the divides that separate them by couching
the drugs in the interest of patient health. Similarly, the discipline of pharmacy and the
assemblage of awareness they compile from a litany of patient interactions, become a site
where negotiations between the patient, the pharmaceutical industry, and the profession
of medicine are negotiated. Essential questions—such as: who deserves medications?
What ethics guide such decision-making? And what to do when the medicines stop
becoming agents of therapy and become agents of harm?—are asked and answered over
the pharmacist’s counter. Yet, the ability of the language with which those in the medical
establishment to adequately answer these questions and slow the trickle of prescriptions
onto the street for abuse is limited. The pharmaceutical industry has adopted ethos of care
(e.g., “what is best for the patient?”) and subsumed this dialogue into a language of
business and profit. It is no small action, as the change to the context with which such
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pharmaceuticals are delivered and consumed is radically transformed. The addict, while
the ultimate consumer, is the antithesis of the patient, cured or treated by the therapeutic
power of pharmaceuticals. Instead, prescription drug abuse constructs addiction and
business as opposed to patient care. The conflicts that emerge regarding the (il)licit use of
prescription drugs allows the professional role of pharmacists and the addicted body to
become sites where micropolitics between dialogues of medicine and care compete with a
pharmaceutical industry agenda centered on profit-generating work.
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